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Adrenomedullin (AM) is a potent hypotensive peptide recently isolated from human 
pheochromocytoma. Although AM is mainly secreted and released from adrenal tissue， 
heart, aorta, vascular smooth muscle cells, kidney, and lung, specific AM binding sites have 
been identified within the central and peripheral nervous systems. Calcitonin gene-related 
peptide (CGRP), a novel neuropeptide, has also been identified in different areas of the 
human brain, as well as in peripheral nerve tissues. Endothelin-3 (ET3)，an isoform of 
Endothelin-1,2,3, was first described as being produced in vascular endothelial cells, but 
has also been identified in the central nervous system (CNS). 
AM belongs to the CGRP family and interacts with AM and CGRPl receptors. 
Receptors for AM and CGRP have been described in rat vascular smooth muscle cells 
(VSMC) and mesangial cells. The endothelin-A receptor predominates on vascular 
smooth muscle cells and is responsible for causing vasoconstriction in both large and 
small blood vessels. A large body of evidence has indicated that vasoactive peptides are 
involved in the control of blood pressure, fluid and electrolyte homeostasis, via both 
peripheral and central mechanisms. 
Astrocytes, the most numerous cell types in the CNS, play a vital role in the proper 
functioning of neurons and in the regulation of metabolic functions within the brain. They 
express various neurotransmitters and neuropeptide receptors. This thesis examines 
astrocyte AM and CGRP receptors, their possible effector systems and interactions. 
Characterization of receptors to both AM and CGRP on mouse astrocytes in primary 
culture shows that they both bind to the cellular binding sites although with different 
maximal binding capacity. In addition, AM- and CGRP-stimulated astrocyte cAMP 
responses can be elicited and were found to be attenuated by activation of protein kinase C 
(PKC). Endothelin (ET), a potent vasoconstrictor hormone and neuropeptide, also 
suppressed AM and CGRP-stimulated cAMP accumulation in a potent maimer. PKC 
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activation may constitute one mechanism through which this occurs. Phorbol 12-myristate 
13-acetate (PMA), an activator of PKC, can attenuate cAMP production in astrocytes in 
response to AM and CGRP, and this suppressive effect can be reversed by the PKC 
antagonists, staurosporine and Ro 31-8220. However, the suppressive effect of ET3 can also 
be reversed by staurosporine and Ro 31-8220. Available data suggests that ET3 exert its 
effects through enhanced activity of certain kinases, with PKC activation playing an 
important role. 
The results described in this thesis support important roles for these vasoactive 
peptides in their regulation of astrocyte metabolism, thus providing an insight into the 
cellular mechanisms underlying the central actions of vasoactive peptides which may be 
pertinent to haemodynamic and body fluid homeostasis. 
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論文擇要 
A d r e n o m e d u 1 1 i n ’ C G R P，E T - 3 
在培養的星形膠質細胞中作用与相互作用 
Adrenomedullin(AM), 一個有降壓功能p e p t i d e ’最近從人嗜恪細 
胞中提取出來•其主要由賢上腺’心臟’主動脈’血管內皮細胞’賢臟和肺所 
分泌•但其在中樞和周圍神經系統中表達特异的結合已被証實• 
Calcitonin gene-related'peptide (CGRP) 一個經典的神經peptide,存在于人體大 
腦及周圍神經系統中• Endothelin-3 ( E T - 3 血管內皮素 3 ) >原先被發現由 
血管內皮細胞產生’現發現其同樣存在于中樞神經系統中• 
A M ‘ C G R P ‘ ET-3的受体’過去已在老鼠血管平滑肌細胞和 







最大結合量和結合力.由AM ’ CG R P -刺激星形膠質細胞產生cAMP的反應 
被發現可以爲旦白酵素c(PKC)所減弱 .ET-3個有收縮血管功能的 
p e p t i d e , 同 樣 有 減 弱 A M , C G R P-刺激細胞產生cAMP的反應,此當 
中PKC激活可能是其中的一個激活路徑.PMA. 一個PKC激活因子,能夠抑制 
cAMP的產生,但其作用可以爲旦白酵素c(PKC)的洁抗因子(Staurosporine/ Ro 31-
8220)所洁抗.同樣E T - 3的抑制cAMP作用可以爲Staurosporine/Ro 31-8220所拮 
抗.由此得出：ET-3可能是,至少部分是,通過PKC激活耒抑制cAMP的產生. 
論文的結果支持血管活性 p e p t i d e (AM. CGRP and ET-3)在血壓控 
制及体液電解質平衡的控制是通過中樞和周圍神經系統的機制實現的觀點,并爲 
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The calcitonin gene peptide superfainily consists of calcitonin (CT), calcitonin 
gene-related peptide (CGRP), and amylin. Together, CGRP, CT, amylin and 
adrenomedullin have overlapping biological effects resulting from their structures and 
cross-reactivity between receptors. The receptors of CT, CGRP, adrenomedullin, and 
amylin belong to a family of G-protein-coupled receptors (Wimalawansa, et al, 1997). 
Extensive studies have shown that these hormones play important roles in electrolyte, fluid 
and circulatory homeostasis. The extensive literature on the actions of vasoactive peptides 
stems largely from studies in peripheral tissues, in particular the heart, blood vessels and 
kidneys. There is however increasing evidence that these vasoactive peptides also exert 
effects through central mechanisms as neuropeptides. 
Astrocytes, which constitute a high proportion of cells in the central nervous system 
(CNS)，used to be regarded as passive supporting elements. In recent years their 
significance in the maintenance of normal brain physiology and their roles in the 
pathophysiology of certain neurological disorders have been realized. More recently, 
adrenomedullin has been shown to bind to astrocytes, with generation of cyclic AMP 
(cAMP)(Yeimg et al, 1996a). The immunoreactive of AM in astrocytes indicates that 
peptides secreted by neurons in nervous systems produce actions, by not only endocrine and 
paracrine effects but also synaptic transmission effects. In this processing, astrocytes play 
important roles in accepting and transmitting biochemical signals. 
This thesis aims to elucidate certain aspects of the biological interactions between 
vasoactive peptides and astrocytes, with emphasis on the underlying biochemical 
mechanisms. This introduction provides background information as a basis for the various 
studies described in the subsequent chapters. It is organized into four sections, namely: 
1. A review of vasoactive peptides and their receptors. 
2. A review of astrocytes, particularly their functions and metabolism. 





I 4. Aims of the thesis. 
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� 1 . 1 VASOACTIVE PEPTIDES 
1.1.1 H I S T O R I C A L B A C K G R O U N D 
Cerebral blood vessels are innervated by three types of perivascular nerves; 
sympathetic fibres storing noradrenaline and neuropeptide Y (NPY), parasympathetic 
nerves storing acetylcholine, vasoactive intestine peptide (VIP), and sensory afferent fibres 
containing calcitonin gene-related peptide (CGRP), substance P (SP) and neurokinin A 
(Uddman and Esvinsson, 1989). 
The interplay between vasoactive peptide systems is an essential determinant of 
blood pressure regulation in mammals. While the endothelin and the renin-angiotensin 
systems raise blood pressure by inducing vasoconstriction and sodium retention, the 
kallikrein-kinin and the natriuretic-peptide systems reduce arterial pressure by eliciting 
vasodilatation and natriuresis (Pesquero and Bader, 1998). 
Among the vasoactive peptides, the natriuretic peptides exhibit broad and disparate 
effects at multiple sites in the cardiovascular system. Atrial natriuretic peptide (ANP) 
inhibits the renin-angiotensin-aldosterone axis: ANP decreases renin secretion from the 
macula densa (Burnett et al., 1984)，directly inhibits aldosterone secretion from the zona 
glomerulosa, and attenuates the stimulatory effect of angiotensin II on aldosterone release 
(Atarashi et al.，1985). In addition to natriuresis, which is mediated by the inhibition of 
sodium transport in the collecting duct (Zeidel, 1993), ANP also dilates both arteries and 
veins. Through its stimulation of vagal afferents, ANP inhibits sympathetic nervous 
activity. In addition, ANP can inhibit growth of vascular smooth muscle and endothelial 
cells. The effects of brain natriuretic peptide (BNP) are thought to be identical. In marked 
contrast, c-type natriuretic peptide (CNP) has limited natriuretic and diuretic effects. 
Instead, the actions of CNP appear to be confined to a paracrine form of regulation in which 
CNP acts as a potent vasodilator and inhibitor of vascular cell growth in response to 
18 
mitogens (Suga, et al, 1992). In addition, the natriuretic peptide family has receptors which 
are present on mouse astrocytes and the peptides appear to play a role in activating second 
messengers and signal transduction (Yeung et al, 1993). Peptides released by sensory 
nerves (substance P and calcitonin gene-related peptide) and autonomic nerves 
(neuropeptide Y), or generated by endothelium (angiotensin II) or injured tissues 
(bradykinin), regulate vascular tone, permeability and proliferation (Walsh et al., 1993). 
The discovery of adrenomedullin has added to the growing array of endocrine, 
paracrine and autocrine peptides with potentially important roles in pressure and volume 
homeostasis. Kitamura et al. (1993a) described the isolation of a peptide fraction from an 
acid extract of human pheochromocytoma tissue using monitoring of the ability of the 
extract fraction to generate cyclic AMP (cAMP) in platelets. Subsequent ion exchange 
separation and gas-phase sequencing led to the identification of a 52 amino acid peptide 
containing a single intramolecular disulphide cysteine-to-cysteine bond and a C-
terminal amide group (Fig 1). Present in high concentration not only in 
pheochromocytoma tumour tissue but also in the normal adrenal medulla, the 
polypeptide was named as adrenomedullin. In its C-terminal portion (amino acid 
residues 16-52), adrenomedullin (AM) has 27% sequence similarity to calcitonin gene-
related peptide (CGRP) and may belong to the CGRP super-family of peptides 
(Kitamura et al.’ 1995). As a vasoactive peptide, AM produces sustained hypotensive 
effects when administered to anaesthetized rats (Kitamura et al., 1993a). The presence 
of immunoactive AM has been shown in the circulation. CGRP is a 37-amino acid 
peptide generated from the alternative splicing of the calcitonin gene and, among other 
functions, it is a potent dilator of cerebrovascular smooth muscles (Edvinsson et al., 
1987; Jansen-Olesen et al.，1996). 
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CLn G l y T y r C l y ; ACCJ Acq Keg Ac<y Ar<; S e r Leu. Pco CLu VaL L e u 八eg A i i Arq The v ^ l 
43 1 CAC TC:C TCC Ci\G CAG CAC ACA CAC TCA CCT CCA CCC TCC CCC CCC CAC CAC ATC TCC 
CLu S e c Stc C L n CLu C L n The B i s S-sc A l a P r o Aj.« S s r P r o 八 日 i a CLn Aap IL< S<c 
54 L AC.\ CVC TCT ACC TTA TAG CTC CCC CTG CCA CCA TTC AAC ACT CCC CCC ACT ATC CCA TTC 
A eg VaL S<tc A eg L e u - ' ' 
• » 
5 0 1 CCC CCT CCC CAA TCA CAG ACC TTC CC.i^CCC TCA CCC CAC TCA CAC CTT CCA CAC ATC 
S 6 I TCC CTC CCT CCC CCT fiCC CCA CCC ACA CCA ACC CAA CAT CAA CCC ACC CTC ACC TCA 
1 ^ I ACC CAC /VAT TAG ACC CTC AT^ CTC TCT CCC CCC AGG CCT CTC ACC CAC TCC CTT CCC CCC 
7a I TCA TAA ACT CCT TTT CTC ACC CGG CAT： ACG CCT CAT TAC TAC TTC \AC TTT CCA AAA CCT 
a 4 I ACC CAC CAA AAC TCC KAT CCT TCT TAT AC\ CCC AAA CCT ；VAC TAT CAT ATT TAA CTT TCT. 
9 0 1 TCA TCT CAA C ^ C CTT TTT TTT TTT CTA ACT TCA K,\T ATA TAG TAT TTT TCr ACG TTA 
TAT ATT CTA TTA ACG CCA TTT TAA ACC CAT TAT KTT CTC ACC TTC CCC TAT TTT Kf^G /UNG 
10 2 L TCA M C TCT CAC CAA CCT GTA ACG TTC TTT CCT TCC CTC TCT CTG TCT CTC TCT CTC TCT 
108 I CTG TCT . CTC TCT CTC TCT CTG TiVA CCT CCA CAG CCC CTG ATT ACC CCC TCT CCA TCA AC八 
i l “ •、、》、KAC ATT CTC TCT TCT IVTA ATC TAT TTA CAT ATA TCT GAT CTG CCA AAA AGC WVA 
12CU CCA Ar/\ AAC TCT CTC /VAT CCT C ( ? o l y A) 
Fig 1. Structure of adrenomedullin (Sakata, 1993 with modification). The AATAAA 
sequence is dotted underlined. The arrow indicates the putative signal peptide cleavage site. 
AM and proA]Vf-N20 sequences are boxed. The Gly residues which contribute to C-
terminal aminde structure are dotted boxed. Typical sites for proteolytic cleavage to mature 
peptide are underlined. 
AM shares structural homology with CGRP and amylin. The sequence 
homology of AM with human CGRP (Morris et al., 1984) and amylin (Westermark et 
al.，1986) is not high, although they share a 6-residue ring structure formed by an 
intramolecular disulfide linkage and the C-terminal amide structure. It should be noted 
that the 14-residue N-terminal extension found in AM is not found in CGRP or amylin. 
Hence, AM was first presented with information concerning its structure, amino 
acid sequence’ a probable second messenger (cAMP), the fact that it circulates, and finally 
evidence of powerful hypotensive activity (Kitamura et al.，1993b). Studies into the 
biochemistry, molecular biology, and pharmacology of AM and CGRP have not only 
characterized a class of hormone with important physiological functions, but have also 
provided insights and posed questions, regarding its physiological and pathophysiological 
functions in the heart and the CNS, as well as its regulation of fluid balance and 
haemodynamic homeostasis. 
1.1.1.1 A D R E N O M E D U L L I N 
AM immunoreactivity and mRNA have been identified in the heart, aorta, kidney, 
and lung. As stated above, AM is a 52 amino acid vasodilator peptide, originally discovered 
in human pheochromocytoma, but which is also present in the plasma of healthy subjects 
and patients with hypertension (Kitamura, et al., 1993b). The sequence of AM was reported 
by Sakata et al. (1993): the AM precursor is 185 amino acids in length, including a 21 
residue signal peptide at the N-terminus. Rat AM consist of 50 amino acids similar to, but 
distinct from human AM where 2 residues are deleted and 6 residues are substituted when 
compared to those of the human peptide. In addition to human and rat AM, the structure of 
porcine AM has also been elucidated. Porcine and human AM are identical, with the 
exception of a single replacement of glycine for asparagine at position 40. 
The presence of AM in normal tissue and plasma of humans, and its synthesis and 
release by endothelial cells in vitro, suggest that the peptide may have a physiological role 
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in cardiovascular control in vivo (Cockcroft and Wilkinson, 1998). Furthermore, AM 
immunoreactivity has also been found in the human brain (Ichiki et al.，1994). Satoh et al.， 
(1996) localized AM immunoreactivity in the paraventricular, supraoptic, and infiindibular 
nuclei of the hypothalamus. AM has been demonstrated to act centrally in conscious rats to 
inhibit water drinking and salt appetite (Samson et al.， 1998a). Furthermore, 
intracerebroventricular injection of AM in the rat inhibits vasopressin release and produces 
a diuretic action in the kidney with hypotensive effect (Yokoi et al., 1996). This indicates 
that AM may modify water-electrolyte balance not only by central endocrine effects but 
also by remote endocrine effects via the kidney. AM also has hypotensive effects in the 
peripheral cardiovascular system. Ishiyama et al. (1993) have suggested that the fall in 
blood pressure, together with an increase in cardiac index and stroke volume without a 
change in heart rate, is suggestive of a positive inotropic cardiac effect of AM in 
experiments using intravenous injection of AM in rats. 
Thus AM appears to have an important role in electrolyte, fluid and circulatory 
homeostasis, and in CNS signal transmission systems, in both physiological and 
pathophysiological circumstances. 
1.1.1.2 C A L C I T O N I N G E N E R E L A T E D P E P T I D E 
CGRP was identified in 1983 as an alternative gene product of the calcitonin gene in 
the rat (Rosenfeld et al., 1983). In man, complementary DNA encoding the precusor of 
CGRP was recognized by Steenbergh, et al. (1985) in messenger RNA extracted from 
medullary thyroid carcinoma. Calcitonin (CT)，CGRP, amylin and AM have the N-terminal 
6-7 amino acid ring structures and amidated C-termini in common (Fig 2 )(Fischer and 
Bom, 1985; Westermark, et al., 1986; Kitainura, et al., 1993b). Additional amino acids in 
the middle and C-terminal regions are identical in several peptides. AM has a linear N-
terminal extension of the ring structure of 15 and 13 amino acids in human and rat AM, 
respectively (Kitainura, et al, 1993b). 
21 
U “ 1 10 I ^ 30 40 50 CO 
Human AM HsN-YRQSMhmFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDtWAPRSKISPQGY-CONHs 
Porcine AM 
Hat AM 
Human CGRP H 2 N - ; 4 D T A t 8 j [ v T H R _ L L S R S G G V V _ F V m W / G g K A - F - C O M H 2 
HumanCGRP II H2N-A i ;NTAaK )VTHR I iKGLLSRSGGMV^SS i gFV0TNVGSKA-F-CONH2 
“Human amylin H2N-KLtATCATQRL^FLVHSSNNFGAILSSTNVG;3NT-.V-CONH2 
Fig 2 Comparison of the amino acid sequences of human AM with porcine an drat AM, and with 
human CGRP, CGRP 11 and amylin. Homologous regions are shaded. Each letter in the 
sequence corresponds to 1 amino acid. 
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Calcitonin (CT) is synthesized and secreted from parafollicular or C-cells within 
the thyroid gland (Fischer and Bom, 1985). Calcitonin lowers blood calcium levels 
through inhibition of osteoclastic bone resorption and stimulation of urinary calcium 
excretion. CGRP is also present in C-cells of normal thyroid tissue, although it is most 
evident in tumour cells in medullary thyroid carcinoma, where it is frequently co-stored 
with calcitonin (Sikri et al.，1985). CGRP also appears to be a neuropeptide synthesized 
in neurons of the central and peripheral nervous system. It is a potential vasodilator in 
cardiovascular systems in vivo and in vitro. CGRP dilates a variety of vessels including 
the coronary, cerebral and systemic vasculature. CGRP has been reported to inhibit the 
development of stress-induced ulcers in humans with of administration into the lateral 
brain ventricle, and it also reduces food intake in rats after administration into the lateral 
brain ventricle (Morley et al.，1981; Lutz et al., 1998). Neurons produce high levels of 
CGRP in major telencephalic vocal-control regions in male zebra finches, whereas 
neurons in female finches produce less or none at all. This dramatic neurochemical sex 
difference may be directly related to production of learned vocalizations in males zebra 
finches, as well as to other aspects of song behavior and courtship (Bottjer et al., 1997). 
Binding sites for CGRP with properties consistent with those of receptors are present in 
both the central and peripheral tissues. CGRP receptors are abundant in the brain, and 
the pattern of distribution of receptors is similar in the rat，pig, cow，sheep and in man 
(Wimalawansa and el-Kholy 1993). CGRP receptors were solubilized from rat 
cerebellum membranes in a guanine nucleotide-sensitive form (Chatteijee et al.，1993). 
1.1.1.3 E N D O T H E L I N S ( E N D O T H E L I N - 3 ) 
The endothelins are a group of highly potent vasoconstrictor peptides originally 
isolated from vascular endothelial cells (Yanagisawa, et al, 1987) and subsequently 
found to exist in three isoforms，i.e. endothelin-1, endothelin-2 and endothelin-3. 
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Endothelin has been detected in porcine spinal cord (Shinmi, et al, 1989) and 
hypothalamus and in the posterior pituitary of the pig and rat (Yoshizawa, et al., 1990). 
A functional role for endothelin in the central nervous system has been suggested by 
studies which demonstrate potent cerebrovascular responses following central 
administration of various endothelin peptides. In addition to cerebrovascular 
hemodynamic effects, endothelin-1 given intracistemally has been shown to produce 
severe apnea which was independent of changes in systemic arterial blood pressure 
(Fuxe，1989a). A discrete brain lesion, of ischemic nature, has been demonstrated 
following intraparenchymal adminstration of endothelin-1 into the striatal region of the 
mt brain, indicating that endothelin may contribute to the development of cerebral 
infarcts and neuronal death (Fuxe, 1989b). It has also been suggested that endothelin 
may function as a neuromodulator since it has been observed that endothelin stimulates 
gonadotropin secretion in anteror pituitary cells (Stojilkovic, et al” 1990). Additional 
support for the potential role of endothelin in modulation of brain function has been 
drawn from autoradiographic studies showing a discrete, nonvascular pattern of 
distribution of endothelin-binding sites. 
Specific binding sites for endothelin-1 and endothelin-3 have been demonstrated 
in rat brain. These binding sites have a clear heterogenous distribution among various 
brain regions with a general increase in density in the hindbrain compared to the 
forebmin regions (Nambi et al., 1990). However, functional studies of endothelin and its 
receptors at the cellular level in neuronal tissue, and in particular the secondary 
messenger systems associated with these receptors, are rather limited. 
23 
1.1.2 SYNTHESIS AND RELEASE OF ADRENOMEDULLIN, CALCITONIN 
GENE RELATED PEPTIDE AND E N D O T H E L I N S 
1.1.2.1 SYNTHESIS AND RELEASE OF ADRENOMEDUULIN 
It has been demonstrated that vascular endothelial cells synthesize and secrete AM. 
Immunoreactive AM has been demonstrated in the culture media derived from cultured rat, 
human，pig, and bovine endothelial cells, as well as vascular smooth muscle cells 
(VSMCs). It has also been shown that AM mRNA expression in endothelial cells is 20-40 
times that observed in adrenal gland (Sugo et al, 1995). Table 1 shows a list of substances 
which have been shown to either induce or inhibit the production of AM. Interleukin-1, 
tumour necrosis factor，lipopolysaccharide, adrenocorticosteroids and retinoic acid all result 
in a marked increase in AM production from VSMCs. This suggests that AM production 
from vascular tissues is subject to complex regulation influenced by multiple local and 
circulating factors (Sugo et al., 1994, 1995). 
AM is secreted along with catecholamines, via Ca^-dependent exocytosis, 
following the stimulation of nicotinic acetycholine receptors in bovine cultured adrenal 
medullary cells (Kitamura et al., 1995). Endothelial cells also actively synthesize and 
secrete AM (Sugo et al., 1994) and AM secreted from endothelial cells is thought to act 
directly on vascular smooth muscle cells, with functional antagonism to endothelin-1, to 
regulate vascular tone (Yanagisawa, 1998a). AM also inhibits the production of the 
vasoconstrictive peptide endothelin-1 in vascular smooth muscle cells，probably through a 
cAMP-dependent process (Barker and Corder, 1997). 
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Inducers Inhibitors 




Tumour necrosis factor Vasoactive intestinal peptide 
Epidermal growth factor Interferon-y 
Platelet-derived growth factor 
Acidic fibroblast growth factor 






Adrenallin, etinoic acid 
Phobol ester, thyroid hormones 
Fetal calf serum, Aldosterone 
Dexamethasone, Hydrocortisone 
Table 1 Inducers and inhibitors of cellular production of AM in cultured vascular smooth 
muscle cells (Sugo et al., 1994 and 1995 with modification). 
1.1.2.2 SYNTHESIS AND RELEASE OF CALCITONIN GENE RELATED 
PEPTIDE 
CGRP is a 37-amino-acid neuropeptide that is widely distributed in the central and 
peripheral nervous systems in mammals (Wimalawansa, 1996). CGRP is derived from the 
tissue-specific alternative splicing of the primary transcript of the calcitonin and CGRP 
gene and produced almost exclusively in neuronal tissues (Rosenfeld, et al., 1983; 
Wimalawansa, 1996). The peptide is also secreted with calcitonin from malignant C-cells 
both in man and in rats (Zaidi et al., 1986). CGRP is mainly derived from perivascular and 
cardiac nerves (Zaidi et al., 1985, 1986). Immunocytochemical and radioimmunoassay 
techniques have identified CGRP-containing nerve fibers throughout the cardiovascular 
system，particularly in association with blood vessels (Mulderry et al, 1985). In blood 
vessels these nerves are found at the junction of the adventitia and the media passing into 
the muscle layer (Wimalawansa and Maclntyre, 1988). In these nerve fibers, CGRP is often 
colocalized with substance P and other tachykinins (Yaksh et al., 1988). 
1.1-2.3 SYNTHESIS AND RELEASE OF ENDOTHELINS 
The gene encoding for endothelin-1 can be detected in a wide variety of tissues, 
including endothelial and smooth muscle cells of blood vessels, heart, lung，brain, kidney, 
pancreas and spleen. The gene encoding for endothelin-2 may also be found in the vascular 
endothelium, as well as the smooth muscle of the large and small intestine, myocardium, 
stomach，kidney, placenta and uterus. Endothelin-3 expression predominates in the brain 
but is also found in the lung, gastro-intestinal tract and kidney (Inoue et al., 1989). 
Endothelin-1 is generally thought to be a paracrine and autocrine mediator rather 
than an endocrine hormone. Indeed, endothelin-1 is largely secreted abluminally by 
endothelial cells towards the adjacent vascular smooth muscle (Yoshimoto et al., 1991), so 
that concentrations are likely to be substantially higher at the interface between endothelial 
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and vascular smooth muscle cells than in blood, consistent with a primarily local action. In 
addition, the half-life of endothelin-1 in blood is short, at less than 5 min, with clearance 
predominantly via receptor binding and metabolism in the lungs and kidneys (Dupuis et al., 
1996). 
1.1.3 ADRENOMEDULLIN, CALCITONIN GENE RELATED PEPTIDE AND 
ENDOTHELINS IN THE CNS 
Although many vasoactive peptides (as ANP, endothelin and calcitonin), first 
discovered in peripheral organs, are also present in the CNS, attention has been directed 
to the existence, and the potential actions, of these peptides within the CNS. The 
presence of immunoreactive (IR)-AM has been shown in the rat brain as has the 
expression of AM mRNA in the brain of both man and the rat (Satoh et al., 1995, 1996). 
IR-AM has been detected not only in plasma (Kitamura et al., 1994a), but also in 
cerebrospinal fluid (Takahashi, et al, 1997). IR-AM has been localized in the 
paraventricular, supraoptic, and infundibular nuclei of the hypothalamus (Satoh et al., 
1996) and in the choroid plexus (Washimine, et al, 1995). Specific binding sites for AM 
are present in the cerebral cortex, cerebellum, thalamus, hypothalamus, pons and 
medulla oblongata. Intracerebroventricular injection of AM inhibits water drinking 
(Murphy and Samson, 1995) and feeding (Taylor et al., 1996) in the rat. In addition, 
ICV injection of AM inhibits vasopressin release in the rat (Yokoi et al., 1996). Rat AM 
(11-50) also inhibits basal and corticotropin-releasing hormone-stimulated 
adrenocorticotrophic hormone (ACTH) secretion from dispersed anterior pituitary cells 
in culture (Samson et al” 1995). 
As stated above, CGRP is produced almost exclusively in neuronal tissues 
(Rosenfeld et al., 1983; Wimalawansa et al., 1996). A prominent site of CGRP synthesis 
is the dorsal root ganglia (DRG), which contains the cell bodies of afferent sensory 
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nerves that terminate peripherally on blood vessels and other tissues innervated by the 
sensory nervous system. Centrally it is found in the laminae LOI of the dorsal horn of the 
spinal cord (Gibson et al.，1984). Immunoreactive CGRP-containing nerve fibers are also 
widely distributed in the cardiovascular system. High affinity receptors are also present in 
the nervous system, including the cerebellum, the brain stem and the spinal cord as well as 
in cultured astrocytes (Goltzman and Mitchell 1985). 
With regard to ET-3，recent studies have confirmed that ET exists in endothelium 
and particularly in neuronal cells. Endothelin has been detected in the porcine spinal cord 
(Shinmi et al, 1989) as well as in the hypothalamus and posterior pituitary of the pig and 
rat. 
1.1.4 RECEPTORS OF ADRENOMEDULLIN, CALCITONIN GENE RELATED 
PEPTIDE AND ENDOTHELINS AND SIGNAL TRANSDUCTION 
Most neurotransmitters and neuromodulators that initiate cellular signaling 
processes cannot penetrate the hydrophobic plasma membrane lipid bilayer but, rather, 
transmit their message via cell surface receptors. It has been estimated that about 80% 
of all known hormones, neurotransmitters, and neuromodulators (numbering over 100) 
elicit cellular responses through G proteins coupled to a variety of intracellular effectors 
(Bimbaumer 1990). Cells recognize and respond to external signals by means of their 
signaling pathways. The first of these to be identified was the honiione-stimulated adenylyl 
cyclase pathway, which uses the intracellular second messenger cAMP to transmit signals. 
This pathway has become a paradigm for the concept of second messengers, protein 
phosphorylation, and signal transducers such as heterotrimeric G proteins (Sutherland et 
al., 1995). 
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Adenylate cyclase is a membrane-bound enzyme which catalyzes the conversion 
of adenosine triphosphate (ATP) to cyclic adenosine-3 ’，5 ‘ monophosphate (cAMP). 
cAMP, an intracellular second messenger, activates protein kinases by dissociating its 
regulatory subunit from the catalytic subunit. The free catalytic subunit thereupon 
initiates a series of enzymatic reactions leading to a phosphorylation cascade, activating 
multiple proteins that regulate cellular processes (Ishikawa and Homey, 1997). 
As with other peptide hormones, AM and CGRP must first bind to stereospecific 
cell surface receptors on target cells in order to evoke a physiological response. This 
hormone-receptor interaction leads to activation of second messenger systems. Vascular 
smooth muscle cells possess specific AM receptors functionally coupled to adenylate 
cyclase (Eguchi et al., 1994a). Specific binding sites for AM are present, for example, in 
’ ^ the cerebral cortex, cerebellum, thalamus, hypothalamus, pons and medulla oblongata. 
Three AM fragments, AM(1-12), AM(22-52), and AM(13-52), have been shown to be 
poor inhibitors of the binding of AM(l-52) in human brain, suggesting that the whole 
AM molecule is required for binding to the receptor (Sone et al., 1997). Cultured mouse 
astrocytes possess specific AM receptors which are couple to adenylate cyclase (Yeung 
et al, 1996a). 
Specific CGRP receptors, coupled to adenylate cyclase, have been identified in the 
liver，spleen, heart, skeletal muscle, kidney, pancreatic and parietal gastric cell membranes. 
(Goltzman and Mitchell 1985; Zhou et al., 1986; Maton et al., 1988; Hashimoto et al, 
1989). High affinity receptors have also been identified in the nervous system, including the 
cerebellum, the brain stem and the spinal cord as well as in cultured astrocytes (Goltzman 
and Mitchell 1985). Grey matter has been shown to have a higher density of these receptors 
than white matter (Wimalawansa, 1992). In early preparations from the CNS, CGRP was 
unable to stimulate adenylate cyclase activity (even at high concentration). However, 
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calcitonin gene-related peptides have been found to stimulate cAMP in human 
nonpigmented ciliary epithelial cells (Crook and Yabu 1992)，and preincubation with 
PMA resulted in a inhibition of CGRP-dependent cAMP stimulation production. 
It is now recognized that receptor-mediated inositol phopholipid metabolism 
constitutes an important signal transduction mechanism for many hormones, which bind 
to receptors on the cell surface, stimulate phospholipase C, and ultimately regulate 
cellular metabolism through an increase in intracellular calcium and activation of 
protein kinase C (PKC) (Nishizuka, 1986). Agents that either mimic or elevate 
intracellular cAMP enhance the synthesis of [^H] inositol-containing lipids, and the 
accumulation of inositol phosphates, suggesting that the effects ofrCGRP are mediated, 
at least in part, via the activation of adenylate cyclase (Laufer and Changeux 1989). It 
^ has also been reported that CGRP receptors are required for inhibition of adenylate 
cyclase by the protein kinase C pathway (Crook and Yabu 1992). CGRP-induced 
preconditioning protects the endothelium against injury, the effect of CGRP being 
related to the activation of PKC (Tang et al” 1997). These reports indicate that there are 
positive interactions between cAMP elicited by CGRP and the phosphoinositide 
signaling system. There is, however, very little information regarding the effect of AM 
on phosphoinositide metabolism. 
Thus，cAMP has emerged as the major known mediator of the actions of AM 
and CGRP. AM exerts various biological actions such as vasodilation, bronchodilation 
and natriuresis, by stimulating cAMP production and increasing free Ca++ levels 
through specific receptors (Murabe et al., 1998). As mentioned before, cAMP has been 
considered to be a primary second messenger of AM (Kitamura et al., 1993a). Ishizaka 
et al (1994) and Eguchi et al (1994a) reported that AM increased cAMP in cultured rat 
VSMCs in a dose-dependent manner. AM also increases cAMP in renal tubular cells 
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(Osajima et al., 1995)，mesangial cells (Kohno et al., 1995), and endothelial cells (Kato 
et al., 1995). Thus AM stimulates cAMP production in cells from a number of different 
tissues in rats. 
1.1.5 BIOLOGICAL ACTIONS OF ADRENOMEDULLIN, CALCITONIN GENE 
RELATED PEPTIDE AND ENDOTHELINS 
1.1.5.1 BIOLOGICAL ACTIONS OF ADRENOMEDULLIN 
1.1.5.1.1 HAEMODYNAMIC EFFECTS OF ADRENOMEDULLIN 
AM has potent vasodilator effects both on systemic and various regional 
circulations. Infusion of a high-dose of AM results in a significant decrease in right 
ventricular systolic pressure and right atrial pressure in a heart failure rat model. AM, a 
potent hypotensive peptide, reduces pulmonary arterial pressure and pulmonary vascular 
resistance, and increases pulmonary blood flow. The mRNA for AM and its receptor is 
highly expressed in the lung, suggesting a regulatory role for AM in the pulmonary 
circulation. Plasma levels of AM have been shown to increase in proportion to the extent of 
pulmonary hypertension (Kakishita et al., 1999). High levels of AM in liver cirrhosis 
correlate with features associated with plasma volume expansion, suggesting that, in late 
stages of cirrhosis, AM might contribute to vasodilatation by increasing the generation of 
nitric oxide (Genesca et al., 1999). Plasma AM concentration increases in proportion to the 
severity of heart failure, along with increases in levels of other hormones such as 
acetylcholine, atrial natriuretic peptide, brain natriuretic peptide, renin, and aldosterone, 
which are known to modulate the development of congestive heart failure (Kobayashi et al.， 
1996b). Plasma AM concentrations increase in the acute phase of myocardial infarction in 
proportion with clinical severity，again suggesting a possible role in the pathophysiology of 
myocardial infarction (Miyao et al, 1998). Plasma AM levels are typically in the lower 
picomolar range in normal Immans and concentrations are reported to increase during 
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exercise (Tanaka et al., 1995). These observations, together with known biological effects, 
suggest that the peptide may play an important role in pressure and volume homeostasis. 
1.1.5.1.2 RENAL EFFECTS OF ADRENOMEDULLIN 
Intracerebroventricular injection of AM elicits dose-related increases in arterial 
pressure and renal sympathetic nerve activity. On the other hand, a subpressor dose, by 
intracerebroventricular infusion, of AM causes significant increases in baroreflex 
sensitivities, as assessed by renal sympathetic nerve activity and heart rate, compared with 
vehicle infusion (Matsumura et al” 1999). Chronically infused AM has a hypotensive 
effect accompanied by significant reductions of plasma renin activity and plasma 
aldosterone concentrations in 2K-1C hypertensive and sham-operated rats (Kohan et al., 
1997). It has recently been shown that both rat and human AM potently stimulate cAMP 
formation in cultured rat glomerular mesangial cells (Kohno et al., 1995). Hirata et al. 
(1995) have demonstrated that AM increases GFR and urinary sodium excretion and 
markedly decreases renal vascular resistance in rats. In the same study, videomicroscopic 
analysis revealed that AM increases the diameters of both afferent and efferent arterioles of 
the glomeruli. Intravenous infusion of AM has also been shown to induce diuresis and 
natriuresis without hypotension and, in higher doses, produces beneficial hemodynamic and 
renal vasodilator effects in rats with compensated heart failure (Nagaya, et al, 1999). These 
reports demonstrate that AM exerts its renal effects partially by regulation of the activity of 
the renin-aldosterone system. 
1.1.5.1.3 ENDOCRINE EFFECTS OF ADRENOMEDULLIN 
Kohno et al (1995) found that rat and human AM both inhibit ETl production 
induced by thrombin. Rat AM (11-50) also inhibits basal and corticotropin-releasing 
hormone-stimulated adrenocorticotropic hormone (ACTH) secretion from dispersed 
anterior pituitary cells in culture (Samson et al., 1995). AM inhibits angiotensin-H-
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and potassium-stimulated aldosterone secretion in a dose-dependent manner, with no 
effect on basal secretion (Yamaguchi et al., 1995). AM given alone and in 
combination with BNP induces a marked increase in plasma renin activity (PRA), 
and decrease in plasma aldosterone (Lainchbury et al., 1999). In primary 
aldosteronism due to adrenal adenoma, plasma AM levels are higher at the moment 
of diagnosis and decline after successful adrenal surgery (Letizia et al., 1998). 
1.1.5.1.4 CENTRAL EFFECTS OF ADRENOMEDULLIN 
Peripheral vascular effects of AM can present as either hypotension or hypertension, 
the different effect being model-related. Intracerebroventricular injection of AM inhibits 
water drinking (Murphy and Samson, 1995) and feeding in rats (Taylor et al., 1996). The 
hypotensive effect of AM is thought to result from inhibition of water intake into the gut 
and increased water excretion by the kidney. In addition, intracerebroventricular injection of 
AM inhibits vasopressin release and leads to hypotension in the rat (Yokoi et al., 1996). 
However, AM exerts potent vasodilatory effects in the periphery as well as influencing the 
control of body fluid balance, when injected centrally by the intracerebroventricular rout 
(Allen and Ferguson 1996). These reports indicate that the hypotensive actions of AM are 
based: on its central nervous system effects. However, intracerebroventricular injection of 
> ‘ ‘ 
AM has been shown to induce hypertension, tachycardia and a decrease followed by an 
increase in renal sympathetic nerve activity (RSNA) in rats (Saita et al” 1998). The 
hypertensive effects of both AM and angiotension-H can be blocked by administration of 
phentolamine, indicating actions of the peptides via stimulation of sympathetic nervous 
system function (Samson et al., 1998a). The hypertensive effect of AM appears to result 
from the increase in RSNA in rats. Thus the hypertensive effect of AM is also based on its 
CNS effects. AM may exert its effects on the central control of fluid balance through direct 
actions at the circumventricular organ. 
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AM when intracerebroventricularly administered, shows significant 
gastroprotective activity, and is protective against reserpine-induced gastric lesions, 
suggesting that the action involves sympathetic nerve activity (Clementi et al., 1998). 
The effect of intracistemal injection of rat AM on ethanol-induced gastric lesions in 
conscious rats indicates that AM acts centrally in the brain to prevent ethanol-induced 
gastric lesions (Kaneko et al., 1998). 
1.1.5.2 CALCITONIN GENE RELATED PEPTIDE 
1.1.5.2.1 HAEMODYNAMIC EFFECTS OF CALCITONIN GENE RELATED 
PEPTIDE 
The discovery of specific binding sites in both myocardium and vascular smooth 
muscle (Sigrist et al., 1986; Wimalawansa et al, 1988; Han et al., . 1990) and the 
presence of the peptide in blood plasma (Girgis et al., 1985; Mair et al., 1990) would 
suggest the possibility of a physiologic role for CGRP in the control of cardiovascular 
function. CGRP has been shown to induce a wide range of cardiovascular effects in 
different isolated preparations as well as in intact humans (Gennari and Fisher 1985; 
Marshall et al., 1986; Franco-Cereceda et al., 1987). CGRP has been demonstrated to 
produce a positive inotropic and chronotropic effect in isolated guinea pig atria and in 
rat ventricular cardiomyocytes (Asimakis et al., 1987; Bell and McDermott 1994). 
Furthermore, the peptide is able to increase coronary flow (McEwan et al., 1986) and 
more generally to inhibit vascular tone (Brain et al., 1985; Kawasaki et al., 1988). As 
stated earlier，the peptide is distributed throughout the central and peripheral nervous 
systems and is located mainly in areas involved in cardiovascular function (McEwan et 
al.，1989; DiPette and Wimalawansa 1994). CGRP has been shown to dilate multiple 
vascular beds, with the coronary vasculature being a particularly sensitive target 
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(Asimakis et al., 1987; DiPette et al , 1989). CGRP released from trigeminal 
perivascular sensory nerves in the brain, is an extremely potent dilator of brain vessels 
(Brian et al., 1996). Systemic administration of CGRP decreases BP in a dose-
dependent manner in both normotensive animals and humans as well as in 
spontaneously hypertensive rats (DiPette and Wimalawansa 1994). The primary 
mechanism responsible for this blood pressure lowering is peripheral arterial dilation. 
Therefore, it has been postulated that CGRP plays a role in the modulation of blood 
pressure and/or regional organ blood flows both under normal physiological conditions 
and in the pathophysiology of hypertension (DiPette et al , 1989). In patients with heart 
failure, CGRP causes a dose-dependent increase in cardiac output and decrease in 
pulmonary and systemic vascular resistance and pulmonary artery pressure (Anand et 
… a l . , 1991). 
11.5.2.2 RENAL EFFECTS OF CALCITONIN GENE RELATED PEPTIDE 
Administration of CGRP into the renal pelvis results in an increase in afferent 
renal nerve activity that is blocked by a CGRP receptor antagonist, suggesting the 
presence of CGRP receptors in the renal pelvic area (Gontijo and Kopp 1999). Systemic 
infusion of CGRP progressively normalizes renal plasma flow and GFR, reduced in 
response to a bolus intravenous injection of the vasoconstrictor endothelin-1. This 
indicates that CGRP regulates renal hemodynamics and modulates the deleterious 
effects of vasoconstrictive substances on the kidney (Amuchastegui et al., 1994). 
1.1.5.2.3 ENDOCRINE EFFECTS OF CALCITONIN GENE RELATED 
PEPTIDE 
CGRP is capable of exerting both stimulatory and inhibitory effects on 
acetylcholine release from mucosal-submucosal neurons and gastrin release from antral 
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mucosal G cells in vitro. The inhibitory effects of CGRP on cholinergic discharge and 
gastrin release are believed due to the paracrine effects of somatostatin released from antral 
D cells in rats by a direct action of CGRP (Ren et al., 1992). Gastrointestinal motility and 
secretions are regulated by cerebral nuclei via autonomic efferents in a coordinated fashion. 
Expression of unique neuropeptides in distinct CNS regions facilitates the differentiated 
regulation of visceral functions. CGRP predominantly accounts for sympathetic modulation 
of gastrointestinal motility and secretion. CGRP, together with other neuropeptides, 
coordinates visceral function producing integrated motor and secretory responses that 
facilitate diverse digestive processes (Lenz, 1991). Intracerebroventricular CGRP also 
inhibits rat duodenal bicarbonate secretion by activation of sympathetic efferents, and 
subsequent release of norepinephrine and vasopressin that act on alpha adrenergic and 
vasopressin receptors, respectively (Lenz and Brown 1990). 
1.1.5.2.4 CENTRAL EFFECTS OF CALCITONIN GENE RELATED PEPTIDE 
The stimulation of the spinal cord improves survival in ischemic skin flaps in rat 
models，and it has been shown that this vasodilating effect is mediated by a peripheral 
release of CGRP (Gherardini，et al, 1999). As stated earlier, CGRP has been reported to 
reduce food intake in rats after administration into the lateral brain ventricle, and 
receptors for CGRP in the forebrain may mediate these anorectic effects (Lutz et al., 
1998). Centrally-administered CGRP inhibits the development of stress induced peptic 
ulcers. Although most evidence points to a peripheral role for CGRP in gastric 
cytoprotection, it may also have a central effect, which seems to be produced by 
modulation of central parasympathetic outflow resulting in increased mucosal blood 
flow (Morley et al., 1981). The central pressor and tachycardic effects of 
intracerebroventricular injection of CGRP are mediated by catecholamine release due to 
stimulation of sympathetic nervous system activity (Kuo et al” 1994). 
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1.1 .5 .3 E N D O T H E L I N S 
1 .1 .5 .3 .1 H A E M O D Y A M I C E F F E C T S O F E N D O T H E L I N S 
ET-1 is produced throughout the cardiovascular system; it can exert important 
effects on both the structure and fiinction of vascular smooth muscle cells and cardiac 
myocytes. ET-1 appears to play a central role in the physiological regulation of 
cardiovascular function, particularly in the vasculature (Sam and Colucci 1999). 
Infusion of endothelin-1 causes hypertension, bradycardia and renal, mesenteric and 
hindquarters vasoconstriction. Co-infusion of human alpha-CGRP reduces the 
hypertension and abolishes the hindquarters vasoconstriction caused by endothelin-1 
(Gardiner, 1991). Endothelin may contribute to the spasm of cerebral arteries following 
subarachnoid haemorrhage (Brian, 1996). Plasma ET-1 concentrations are increased in 
moderate and severe heart failure and are correlated with clinical and haemodynamic 
measures of severity. Endothelin-1 contributes to increased vascular tone in cardiac failure 
(Kelly and Whitworth 1999). 
1.1.5.3.2 R E N A L E F F E C T S O F E N D O T H E L I N S 
ET-1 exerts a wide range of biologic effects in the kidney, including constriction 
of most renal vessels, mesangial cell contraction, inhibition of sodium and water 
reabsorption by the nephron, enhancement of glomerular cell proliferation，and 
stimulation of extracellular matrix accumulation (Kohan, 1997). ET-1 at low plasma 
concentrations increases sodium excretion while a higher pressor dose of ET-1 is 
antinatriuretic. However, increases in plasma ET-1 seem to elicit diuresis over a wide 
concentration range (Sandgaard and Bie 1996). In patients with severe refractory heart 
failure, glomerular filtration rate and renal plasma flow were considerably reduced and 
exhibited a tendency to correlate inversely with high ET concentration (KosKos et al., 
1998). Endothelins also inhibit vasopressin-stimulated cAMP accumulation and water 
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reabsorption in the collecting duct; and may also inhibit sodium reabsorption in the 
proximal tubule and collecting duct. Autocrine inhibition of sodium and water 
reabsorption in the inner medullary collecting duct by ET may play a role in 
maintaining extracellular fluid volume homeostasis (Kohan，1996). 
1.1 .5 .3 .3 E N D O C R I N E E F F E C T S O F E N D O T H E L I N S 
Endothelins affect hormone secretion from a variety of endocrine organs including 
• 2+ 
anterior and posterior pituitary gland, atria and the adrenal gland. They activate the Ca -
messenger system, which involves both calmodulin and protein kinase C, to exert their 
biological activities in almost all cell types examined, and appear to work in a paracrine and 
autocrine fashion. (Takuwa 1993). Intracerebroventricular injection of ET causes 
hypermetabolic responses in 9 neuroendocrine structures, including the pineal gland, 
subfornical organ, median eminence, the hypothalamic paraventricular and supraoptic 
nuclei，and other hypothalamic and preoptic structures (Gross et al., 1993). ET was also as 
potent as hypothalamic gonadotropin-releasing hormone in provoking stimulation of 
gonadotropin release in pituitary cells (Stojilkovic et al, 1990). 
1.1.5.3.4 C E N T R A L E F F E C T S O F E N D O T H E L I N S 
Intracerebro ventricular injections of ET-1 are reported to cause dose-related 
increases in sympathetic nerve activity and blood pressure in anesthetized normotensive rats 
(Nakamura et al., 1999). Intracerebro ventricular and intra-arterial administration of very 
low doses of ET-1 produce hypertension in trout (le Mevel et al., 1999). The intrathecal 
injection of endothelins in rats has been found to lead to respiratory arrest, and the injection 
of ET-1 and ET-3 at T-8 spinal cord level, enhanced vascular permeability in the lungs by 
22-fold and 7-fold respectively (Poulat and Couture 1998). Thus, ET-1 and ET-3 could play 
a role in the development of neurogenic pulmonary oedema, operating through a central 
mechanism. Injection of ET-1 just above the hypoglossal roots, lateral to the pyramids, 
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causes ventilatory depression mediated through ET-A receptors located in the 
chemosensitive areas of the ventrolateral medulla (Dreshaj et al.，1995). Injection of low 
concentrations of ET-3 into the nucleus of the solitary tract increases blood pressure and 
heart rate, whereas ET-3 injection into the area postrema produces a prominent dose-related 
decrease in blood pressure and heart rate (Mosqueda-Garcia et al., 1993). 
1.1.6. P R O L I F E R A T I V E O R A N T I P R O L I F E R A T I V E E F F E C T S 
AM acts as a growth modulator in the vasculature. The effects of AM on protein 
tyrosine phosphorylation, mitogen-activated protein kinase (MAPK) activation, 
protooncogene expression, DNA synthesis, and cell proliferation have been studied in 
cultured rat vascular smooth muscle cells (VSMC). Both AM and CGRP, stimulate DNA 
synthesis and cell proliferation of quiescent VSMC, these effects being inhibited by a 
CGRP receptor antagonist, CGRP-(8-37) (Iwasaki, et al, 1998). 
Similarly, CGRP increases both cell number and DNA synthesis in cultured 
endothelial cells (Haegerstrand et al., 1990). In vivo, CGRP has been shown to stimulate 
angiogenesis. CGRP exerts potent proliferative stimuli in cultured fibroblasts (Nilsson et 
al., 1985;Kahler et al, 1996). 
In other cell types such as numerous human tumor cells, AM has been shown to 
stimulate cell proliferation in a cAMP-dependent manner (Miller et al., 1996; Withers et 
al., 1996). AM potently inhibits proliferation of mesangial cells and VSMC. This effect 
is likely to be mediated mainly via the cAMP pathway via inhibition of the mitogen-
activated protein kinase cascade (Chini et al.,1995; Haneda,1996). AM inhibits fetal calf 
serum-stimulated proliferation in cultured rat VSMCs, probably through a cyclic AMP-
dependent process. With the finding that AM is synthesized in and secreted from 
vascular endothelial cells, AM may play a role as an antiproliferative factor for VSMCs 
in a paracrine fashion (Kano, et al, 1996). 
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1.1.7 C L I N I C A L R E L E V A N C E O F V A S O A C T I V E P E P T I D E S 
1.1.7.1 C L I N I C A L R E L E V A N C E O F A D R E N O M E D U L L I N 
AM plasma concentrations increase in disorders such as heart and renal failure and 
hypertension. In heart failure，this correlates with functional status and other markers of 
ventricular reserve, e.g. brain natriuretic peptide, suggesting that this may be part of the 
haemodynamic response, collectively opposing the local and circulating vasoconstrictor and 
sodium-retaining factors such as noradrenaline, angiotensin n and ET (Cavero et al., 1996). 
The greater effect of AM in patients with essential hypertension suggests that the peptide 
might actively participate in the regulation of membrane functions in hypertension (Tsuda 
et al., 1999). Plasma AM concentrations have been shown to be increased in heart failure or 
chronic renal failure (Ishimitsu et al., 1994; Jougasaki et al.，1995; Nishikimi et al., 1995). 
Previous reports have shown that plasma AM concentrations are increased in patients with 
essential hypertension, especially in those with organ damage, compared with healthy 
control subjects (Ishimitsu, et al, 1994). Furthermore, it has been demonstrated that plasma 
AM concentrations are increased in hypertensive patients with left ventricular hypertrophy 
(LVH) compared to those without LVH, and plasma AM concentrations are weakly but 
significantly correlated with left ventricular mean wall thickness (Sumimoto, et al, 1997). 
Jougasaki et al (1995) previously reported that AM immunoreactivity was more intense in 
the failing human heart than in the normal heart. Recently, this group has demonstrated that 
the heart actually secretes AM into the circulation, by providing evidence for higher plasma 
AM concentrations in the coronary sinus than in the aorta of patients with severe heart 
failure (Jougasaki M, et al, 1996). These results raise the possibility that the failing heart 
produces and secretes more AM into the circulation. Circulating levels of AM are increased 
in patients with cirrhosis and ascites and correlate with hemodynamic and renal 
abnormalities and activation of vasoconstrictor systems. These increased levels seem to 
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result from a generalized increase in AM production from vascular tissue and are not 
suppressed by plasma expansion (Guevara et al.，1998). 
1.1.7 .2 C L I N I C A L R E L E V A N C E O F C A L C I T O N I N G E N E R E L A T E D 
P E P T I D E 
Sensory nerves contain immunoreactivity to the vasodilators substance P and 
CGRP. On the other hand, immunoreactivity to the vasoconstrictor, ET, has been 
demonstrated throughout the endothelial cell layer of human coronary arteries and veins 
(Saetrum and Edvinsson 1998). CGRP improves myocardial contractility in patients with 
congestive heart failure (Gennari et al., 1990). CGRP also presents a new potential drug 
therapy for the treatment of essential hypertension (Tang et al, 1989). CGRP regulates 
vascular adaptations during pregnancy and these effects may be progesterone-dependent. 
Thus combination treatment using CGRP plus progesterone may be a promising therapy in 
the management of pre-eclamptic toxemia (PET) in humans (Wimalawansa et al.，1998). 
The possibility of taking advantage of the vasodilatory activity of CGRP is being 
considered in Raynaud's disease and erectile disfunction of the penis (Gomez-Bezares and 
Vazquez-Doval, 1997). A combination of CGRP and prostaglandin El (PGEl) may be an 
alternative to penile implants in selected patients (Truss, et al, 1994). CGRP can prevent 
cerebral vasospasm after subarachnoid haemorrhage (SAH) and may have significant 
potential for the treatment of patients with SAH (Inoue et al., 1996). Treatment with CGRP 
synergistically potentiated urokinase (UK)-induced vascular recanalization in a dose-
dependent manner, and an antagonist of CGRP (CGRP8-37) significantly attenuated the 
recanalization action of UK (Ding et al., 1993). It has been shown that in humans with a 
compromised circulation, CGRP provides a pharmacologic tool to improve blood flow in 
surgical and traumatic flaps (Jembeck and Dalsgaard, 1993). The finding that the carotid 
vascular beds are sensitive to CGRP, suggests that the drug may help to prevent ischaemic 
deterioration after surgery for aneurysmal subarachnoid haemorrhage (Anonymous 1992). 
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1.1.7 .3 C L I N I C A L R E L E V A N C E O F E N D O T H E L I N S 
Plasma ET-1 concentrations increase following myocardial infarction and 
persistent elevation predicts an increased mortality within the subsequent 12 months. 
It has also been shown that reduction of the activity of the ET system may have a 
beneficial effect in heart failure and myocardial infarction (Kelly and Whitworth 
1999). Plasma big ET-1 and ET-1 levels are strongly related to survival in patents 
with congestive heart failure (CHF) (Wada et al., 1999). Cardiac myocytes and 
vascular endothelial cells produce ET-1, which increases the contractility of cardiac 
muscle and of vascular smooth muscle. ET-1 also exerts long-term effects, such as 
myocardial hypertrophy, and causes cellular injury in cardiac myocytes. In heart 
failure, the production of ET-1 is markedly increased in the failing heart (Miyauchi 
and Goto 1999). ET-1 receptor antagonists improve ventricular remodeling and 
survival, following long-term administration (Sam and Colucci 1999). Sleep apnea 
elicits increases in blood pressure and endothelin-1, with reductions in both after 
treatment (Phillips et al., 1999). 
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1.2 A S T R O C Y T E S 
1.2.1 H I S T O R I C A L B A C K G R O U N D A N D A S T R O C Y T E M O R P H O L O G Y 
A significant non-neuronal component in the nervous system was first 
recognized by Virchow (1858). He considered that the main function of these cells was 
to join neuronal elements together, and he referred to them as neuroglia (nerve glue). 
Named for their star-like shape, astrocytes have been known since the late 19th century 
(Andriezen 1893; Cajal 1913). In the adult human brain, normal astrocytes constitute 
nearly 40% of the total central nervous system (CNS) cell population and may assume a 
star-shaped configuration resembling epithelial cells insofar as the astrocytes remain 
intimately associated, through their cytoplasmic extensions, with the basement 
membrane of the capillary endothelial cells and the basal lamina of the glial limitans 
extern. Although their exact function remains unknown, astrocytes are thought to 
subserve an important supportive role for neurones, providing a favourable ionic 
environment, modulating extracellular levels of neurotransmitters, and serving as 
spacers that organize neurones. 
In immunohistochemical preparations, normal, reactive, and neoplastic 
astrocytes may be positively identified and distinguished from other CNS cell types by 
the expression of the astrocyte-specific intermediate filament glial fibrillary acidic 
protein (GFAP), a specific marker for astrocytes and a principal component of the 10 
nm intermediate filaments found within these cells (Eng, 1980). 
The importance of glial cells is further suggested by their increasing number during 
evolution, as they constitute 25, 65 and 90% of cells of the fly, rodent, and human brain, 
respectively (Pfrieger and Baires 1995). This is somewhat paradoxical in light of the fact 
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that glial cells are the most abundant cells in the central nervous system (Amundson, 1992). 
There are between 10 and 50 times more glial cells than neurones in the CNS. 
Glial cells can be classified into microglia and macroglia. Microglia are derived 
from macroglia, and are embryologically unrelated to other cell types in the CNS. 
Macroglia, which account for 90-95% of glial cells, consist of oligodendrocytes 
(oligodendroglia) and astrocyts(astroglia). Oligodendrocytes are responsible for 
producing the myelin sheaths, which surround axons. 
Morphologically, astrocytes can be classified as protoplasmic (Type 1) and fibrous 
(Type n) (Duffy 1983; Raff et al 1983). The protoplasmic astrocyte possesses numerous 
thick, short processes, and is located abundantly in the cortical grey matter around nerve 
bodies, axons and synapses. The fibrous astrocytes have long, slender cytoplasmic 
processes, and are found chiefly among bundles of myelinated nerve fibres and blood 
vessels in the white matter (Segarra 1970; Duffy 1983). Under cell culture conditions, the 
protoplasmic astrocyte can be made to adopt a neuron-like process-bearing morphology 
in the presence of raise cAMP levels, as with the addition of dibutyryl cAMP or 
theophylline (Moonen et al 1975; Raff et al 1983). This morphological 
alteration/differentiation is associated with enhancement of carbonic anhydrase and Na+, 
K+-ATPase activities (Shapiro 1973; Narumi et al 1978). 
The heterogeneous nature of astrocytes is illustrated by the occurrence of different 
concentrations of soluble GFAP and glutamine synthetase (GS) in different regions of the 
rat CNS. Corpus striatum and spinal cord astrocytes contain the lowest concentrations of 
GFAP and GS respectively, whereas astrocytes in the olfactory bulb show the highest levels 
of GFAP and GS activity (Patel et al., 1985). B-adrenoceptors are located much more 
predominantly on protoplasmic astrocytes than on fibrous astrocytes (Burgess et al., 1985). 
Functionally, protasmic astrocytes serve to direct the migration of neurones (Hatten and 
43 
Mason, 1986), whereas fibrous astrocytes contribute to the structure of the Nodes of 
Ranvier (Ffrench-Constant and Raff 1988). 
1.2.2 P H Y S I O L O G I C A L R O L E S O F A S T R O C Y T E S 
Until the 1970s, glials cells were generally thought to be passive physical supportive 
elements for neurones. The development of glial cell culture techniques has, however, 
improved substantially our knowledge of astroglial cell characteristics and physiological 
functions within the brain. They are now known to be vital to the maintenance of normal 
physiology, metabolism, and development within the CNS. Interactions between astrocytes 
and neurones are crucial to normal neuronal function and metabolism. Astrocytes are likely 
to play a major role in inducing the endothelin cells of the brain capillaries to form the tight 
junctions characteristic of the blood-brain barrier, which assists the transport of nutrients to, 
and waste products from, neurons and protects them from exposure to toxins in the 
circulation (Stewart and Coomber 1986). 
Glutamate and aspartate function as excitatory amino acids in the CNS, whereas y-
aminobutyric acid (GABA) is inhibitory (Watkins and Evans 1981). Several lines of 
evidence suggest that these neurotransmitters, after release into the synaptic cleft during 
neuronal activity, are avidly taken up by astrocytes (Schousboe et al 1977; Yu et al 1986). 
Glutamine synthetase, localized exclusively to astrocytes, represents a major pathway for 
the metabolism of glutamate (Yu et al, 1982). The glutamine is then transported to 
neurones, where it becomes the substrate for further glutamate and GAB A synthesis and 
subsequent release as neurotransmitters. This recycling process is important for proper 
neuronal functioning and normal impulse transmission. Recent evidence has emerged that 
astrocytes can also evoke direct stimulation, and modulate signal transmission, in neurones 
(Nedergaard, 1994). 
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The ionic composition of the milieu around neurones is essential to their effective 
functioning. Astrocytes have developed morphological and physiological adaptations， 
which allow regulation of extracellular potassium generated by neuronal activity. These 
adaptations include: (1) intimate associations between astrocytic processes and neuronal 
synapses where the greatest ion fluxes occur (Ariyasu et al., 1985), (2) high K+ permeability 
at the end feet of these processes (Newman, 1986), (3) increased Na+, K+-ATPase and 
Na7K7CL- cotransporter activities in response to elevated extracellular K+ (Walz and 
Hinks, 1985), and (4) presence of K channels on cell membranes (Bevan and Raff 1985). 
KufFer et al (1966) first showed that the resting potential of astrocytes is exclusively 
determined by their high permeability to K+. As a result, astrocytes can take up excess K+ 
generated by increased neuronal activity to protect nearby neurones from depolarization. 
The K+ can diffuse through large glial syncytia, formed by astrocytic cytoplasmic bridges, 
to the extracellular milieu of more distant, interactive neurones (Gardner, 1983). Thus 
regulation of the neuronal microenvironment by astrocytes acts to stabilize the extracellular 
milieu, helps to buffer the activity of neurones, and thereby protects the environment of 
their neighboring neurones. 
1.2.3 PATHOLOGY OF ASTROCYTES 
Astrocytes are involved in the pathogenesis of various forms of brain oedema. 
Pathological conditions in which astroglial swelling is observed include status 
epilepticus (Siesjo, 1981), ischaemia (Garcia and Lossinsky, 1979), hepatic 
encephalopathy (Norenberg, 1981) and head trauma (Bakay et al., 1977). 
Hepatic encephalophathy is a complex and ill-understood state, but ammonia has 
been implicated as a major pathogenic factor. Increased ammonia levels have been 
shown to lead to astrocyte swelling (Norenberg et al., 1991), depletion of glycogen 
stores (Dombro et al., 1993) and a reduction of calcium influx in to astrocytes (Neary et 
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al., 1990), potentially causing disruption in glial-neuronal signalling and metabolic 
homeostasis. 
Ischaemia and hypoxia result in reduced activity of energy-requiring ion pumps, 
particularly Na+, K+-ATPase. This leads to failure to remove Na+ which has entered the 
cell, resulting in astroglial swelling and oedema. Nevertheless, there is in-vitro evidence 
that astrocytes protect against neuronal degeneration during hypoxia. Although the 
exact mechanism remains to be defined, this may involve astrocytic maintenance by 
astrocytes, of the levels of excitatory amino acids, supply of nutrients to neurones, and 
release of neurotrophic factors (Vibulsreth et al., 1987; Brenneman et al., 1990). 
Gliotic scar formation from reactive astrocytes in response to injury occurs in 
post-traumatic epilpsy (Penfield and Humphreys, 1940). Alteration in enzymatic 
activities within astrocytes associated with an epileptic focus may contribute to the 
development of epilepsy. In regard to this, inhibition of glutamine synthetase by 
methione sulfoximine, which blocks the metabolism of the exitatory amino acid 
glutamate, has been shown to precipitate seizures (Rowe and Meister, 1970). 
Astrogliosis is a prominent feature of epileptic foci, and may play a causal role 
in the development of seizures and the persistence of seizure disorders (Khurgel and 
Ivy, 1996). These authors have studied morphological changes in astrocytes with 
respect to the evolution of seizures using the kindling model of epilepsy. Kindling-
induced seizures result in prominent hypertrophy of astrocytes that is accompanied by a 
reorganization of the astrocytic cytoskeleton. The change in the morphology of 
astrocytes appears to be seizure-intensity dependent, occurs early in the kindling 
process, and persists for weeks following the last seizure. In addition to hypertrophy, an 
increase in proliferation of astrocytes in hippocampus, amygdala and piriform cortex 
suggests that 'gliosis' may be an adaptive response to seizures (Khurgel and Ivy, 1996). 
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1.3 N E U R O P E P T I D E R E C E P T O R S A N D A S T R O C Y T E S 
1.3.1 N E U R O P E P T I D E R E C E P T O R S O N A S T R O C Y T E S 
Evidence for the presence of transmitter receptors on astrocytes has come 
from studies using a variety of experimental techniques. These include 
electrophysiological recordings, ligand binding and the receptor activated generation 
of intracellular second messengers. It has been shown that, at least in vitro, astrocytes 
have functional receptors to monoamines, purones, amino acids, prostanoids and 
peptides. Indeed, they possess receptors to the great majority of neurotransmitters 
found in the CNS (Travis, 1994). 
In the early 1970s, it was first reported that catecholamines could lead to the 
accumulation of cAMP in primary cultures of immature brain cells (Gilman and Schrier, 
1972). It soon became apparent that astroglia could harbour functional receptors to 
certain neurotransmitters. In 1980, Van Calker extended these preliminary observations 
to peptides, by showing that vasoactive intestinal peptide (VIP), secretin, and 
somatostatin could also regulate cAMP in cultured astrocytes incubated in the presence 
of phophodiesterase inhibitors (Van Calker et al., 1980). In the following years, several 
reports established that many other neuropeptides could regulate cAMP in astrocytes 
from mouse, rat, or chick brains. In recent years, it has become apparent that astrocytes 
(at least in vitro) harbour functional receptors to almost all possible neurotransmitters. 
There is considerable evidence that astrocytes possess adrenoceptors of both a and P 
subtypes. Primary cultured astrocytes possess a-adrenoceptors (Ebersolt et al., 1981; 
Hosli and Hosli, 1982), and also possess p-adrenoceptors (Burgess et al., 1985). 
Binding sites for galanin, and cholinergic receptors have also been observed on 
astrocytes (Hosli et al., 1997). It has been shown that astrocytes possess dopamine 
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receptors linked to adenylate cyclase (Henn et al., 1980). Receptors for cholecystokinin 
and bombesin have been identified on the membrane potential of astrocytes in explant 
cultures from rat cortex, cerebellum, brain stem and spinal cord (Hosli and Hosli, 
1993b). Binding sites for the vasoactive peptides ^^^I-neuropeptide Y (NPY) and 3H-
bradykinin (BK) have been found in explant cultures astrocytes of rat cerebellum, brain 
stem and spinal cord (Hosli and Hosli, 1993 a). Several neurotransmitters including 
noradrenaline and VIP induce a glycogenolytic response in cultured astrocytes (Pellerin 
et al., 1997). There is substantial evidence for the presence of receptors for peptide 
hormones and opioids on astrocytes. Primary cultures of astrocytes from neonatal 
murine brain have been reported to express multiple receptors (bombesin, luteinizing 
hormone-releasing hormone, neurotensin, thyrotropin-releasing hormone, somatostatin, 
secretin, vasopressin and catecholamine) that regulate adenylate cyclase activity (Evans 
et al., 1984). Many have the ability to stimulate adenylate cyclase, for example VIP, 
ACTH and PTH (Loffler et al., 1982; Evans et al., 1984; Chneiweiss et al., 1985). In 
addition, it has recently been shown that rat atrial natriuretic peptide elevates the cGMP 
content of astrocyte primary cultures (Friedl et al., 1985, 1986). cAMP accumulation in 
astroglia is also stimulated by catecholamines (acting at beta 1-adrenergic receptors), 
prostaglandinEl, VEP, alpha-melanocyte-stimulating hormone, and adrenocorticotropin. 
However catecholamines, acting at alpha 2-adrenergic receptors, and somatostatin 
inhibited agonist-stimulated cAMP accumulation (Evans et al., 1984). In cultured 
murine brain cells mainly consisting of glioblasts, parathyroid hormone and calcitonin 
stimulate the accumulation of cAMP (Loffler and Van Calker, 1982). ACTH and alpha-
melanotropin (MSH) elevate the intracellular level of cAMP in cultured astrocytes (Van 
Calker et al, 1983). These receptors are linked to membrane inositol phospholipids, the 
break down of which results in the generation of intracellular second messengers which 
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cause the mobilization of intracellular Ca^^ and the activation of protein kinase C 
(Berridge, 1984; Berridge and Irvine 1984). 
Ligand binding studies have also revealed the presence of receptors for ETs 
(Couraud et al., 1991) and for natriuretic peptides (Yeung et al, 1993). As mentioned 
before, cAMP has been considered to be a primary second messenger for AM (Kitamura 
et al., 1993a). Very recently, AM receptor binding experiments indicated that AM 
stimulates cAMP production in cultured astrocytes (Yeung et al., 1998). Specific CGRP 
receptors coupled to adenylate cyclase have also been identified in astrocytes and other 
tissue cells (Goltzman and Mitchell 1985). ETs activate several second messenger 
• 2+ • mechanisms in astrocytes, as they induce pronounced intracellular Ca transients 
(Goldman et al, 1991), and activate mitogen-activated protein kinases (MAPK) 
(Cazaubon et al., 1993), phospholipase A2 (Christain et al, 1995), and phospolipase D 
(Desahger et al., 1996). Accordingly, AM, CGRP and ETs may bind to specific 
receptors coupled to adenylate cyclase to stimulate cAMP production in astrocytes. All 
the peptides listed in Table 2 are usually referred to as "neuropeptides" on the basis of 
the fact that they have been found to affect the behaviour of neurones (Christain, 1998). 
1.3.2 CONSEQUENCES OF RECEPTOR ACTIVATION 
What follows is a brief description of functions ascribed to astrocytes, followed 
by the short-term effects of receptor agonists and finally the evidence for modification 
of known, or unmasking of new functions by, receptor activation. 
It is clear that astrocytes accumulate, store and release various substances. 
Astrocytes are effective in clearing KT from the extracellular space and thereby maintain 
a low and constant K7 environment around neurones (Kimelberg 1983). They are also 
implicated in clearance of neuronally released amino acids and amines. While the 
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Table 2 Neuropeptide receptors on cultured astrocytes. The table summarized the different 
techniques used to detect peptide receptors on cultured astrocytes of different animal ； 
models. It also shows that there is other second messenger mechanism activated by peptides 
on astrocytes as well as cAMP. Abbreviations are: AR, autoradiography; kinetic, 
characterization of receptors by kinetic binding; depol.’ depolarization; hyperpol., 
hyperpolarization; hybrid., hybridization; RT-PCR, reverse transcriptase-polymerase chain 
reaction. 
uptake of excitatory amino acids such as glutamine and aspartate appears to occur 
predominantly into astrocytes, these cells accumulate GABA more slowly than, for 
example, neurones (Currie and Kelly, 1981). 
A major site of glycogen storage in the CNS is within astrocytes (Phelps, 1972). 
It has been suggested that neurones acquire metabolically useful citric acid cycle 
intermediates from neighboring astroglial cells (Shank and Campell, 1984).Astrocytes 
certainly release pyruvate, lactate and alpha-ketoglutarate (Selak et al., 1985). The 
immediate effect of receptor activation on astrocytes, in common with other cell types, 
is one or more of the following: alterations in ion flux, generation of second messengers 
such as cAMP, IPS and diacyglycerol. Basically，the evidence for long-term 
consequences following receptor activation comes from five sources: changes in 
glycogen status, enhances in release of amino acids and eicosanoids, changes in 
cytoskeletal proteins, changes in morphology, and finally changes in proliferation rate 
(Murphy and Pearce 1987). 
1.4 AIMS OF THE THESIS 
Abundant evidence indicates that vasoactive peptides play important roles in the 
central and peripheral control of blood pressure and body fluid homeostasis. The 
vasoactive peptides are usually referred to as "neuropeptides" on the basis of the fact 
that they have been found to affect the behaviour of neurones. The presence of AM has 
been shown in the brain of the human and the rat (Satoh et al., 1995, 1996), and CGRP 
is produced almost exclusively in neuronal tissues (Wimalawansa et al., 1996; 
Rosenfeld et al., 1983). AM receptor binding experiments indicate that AM stimulates 
cAMP production in cultures astrocytes (Yeung et al., 1998). Receptors for CGRP have 
also been identified in the nervous system and in cultured astrocytes (Goltzman and 
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Mitchell, 1985). Data indicate that vasoactive peptides are produced by neurones, while 
astrocyte cells possess specific receptors for vasoactive peptides. Therefore, astrocytes 
are likely to be important target cells of vasoactive peptides within the brain. Further, as 
described in Section 1.2.2, astrocytes in the CNS assist the transport of nutrients to, and 
waste products from, neurons and protects neurons from exposure to toxins in the 
circulation. Thus astrocytes are essential to normal neuronal function and brain physiology. 
Therefore, astrocyte cells constitute an appropriate model to investigate further, the actions 
of vasoactive peptides within the CNS. 
There are, however, pratical difficulties and it is ethically difficult or impossible to 
perform definitive studies in man. As the CNS consists of heterogeneous cell populations 
and systems, studies of vasoactive peptides and glial cells using in-vivo animal models or 
in-vitro explant cultures are subject to the influence of the diversity of cell types and their 
different functions within the brain. Using cell culture techniques, we have isolated mouse 
astrocytes to eliminate the confounding effects of neurones and other cells within the CNS. 
Thus, vasoactive peptides and their receptor-effector functions in astrocytes were examined 
specifically. There are, of course, limitations to this in-vivo cell model. Cultured cells are 
grown in chemically defined medium and are devoid of interactions with other cell types in 
a living animal. Therefore, the cell characteristics may alter, and the cellular responses to 
hormones may not accurately reflect what actually happens under normal but complex 
physiological situations. Thus, the results of the experiments have to be interpreted with 
caution and cannot be directly projected to in-vivo situations. Nor can studies using glial 
cells from animals necessarily be extrapolated to the human situation. However, as the 
culture conditions can be controlled and defined to address specific experimental issues, cell 
culture techniques allow studies of the mechanisms of actions of neurohormones at the 
cellular level, which cannot be achieved in in-vivo studies. In these studies, a single cell 
type-culture as opposed to co-culture or brain slices, was therefore explored. 
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With regard to the animal origin of vasoactive peptides used in our studies, rat AM 
is structurally identical to mouse AM, (Cameron and Fleming, 1998), and CGRP-37 is 
identical in rats and mice (Pomerleau et al., 1997). Thus, rat AM and CGRP are also murine 
vasoactive peptides and are appropriate for the studies in mouse astrocytes. 
The central aim of this thesis is to examine further the biological interactions of 
vasoactive peptides with astrocyte cells. The cells employed were fetal mouse astrocytes in 
primary culture. The specific aims of each individual study were as follows: 
1. To characterize the receptors and second messenger systems of AM in astrocytes. 
Experiments were performed with AM to study its binding characteristics, and their effect 
on cAMP production. 
2. To characterize the receptors and second messenger systems of CGRP in astrocytes. 
Experiments were performed with CGRP to study its binding characteristics, and their 
effect on cAMP production. 
3. To explore the biochemical mechanisms underlying the interactions between vasoactive 
peptides and ET. The effect of ET on AM and CGRP -dependent cAMP accumulation was 
examined. 
4. To explore biochemical mechanisms underlying the interactions between AM, CGRP and 
the protein kinase C (PKC)- agonist, phorbol 12-myristate 13-acetate (PMA), as well the 
PKC-antagonist, staurosporine. Astrocytes were treated with PMA and staurosporine and 
their effects on AM and CGRP -dependent cAMP accumulation were examined. 
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CHAPTER 2 
GENERAL MATERIALS, METHODS 
AND DATA ANALYSIS 
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2.1 M A T E R I A L S 
2 .1 .1 A N I M A L S 
Neonatal International Cancer research (ICR) mice were obtained from the Animal 
House of the Chinese University of Hong Kong. Astrocyte cultures derived from these 
neonatal mice were used for all experiments. 
2 .1 .2 P E P T I D E H O R M O N E S 
Rat AM and rat calcitonin gene-relate peptide (CGRP) were purchased from 
Bachem AG company (Bubendorf, Switzerland). All peptides were reconstituted in distilled 
o 
water at a concentration of 100 |JM and stored in aliquots at -70 C until use. Endothelin-3 
(ET-3) was also purchased from Bachem AG company (Bubendorf, Switzerland). Phorbol 
12-myristate 13-acetate (PMA), phorbol 12,13-dibutyrate (PDBu), and alpha-phorbol 
12,13-didecanoate (aPDD) were purchased from Sigma Chemical Company, Saint Louis, 
Missouri, USA. Staurosporine was procured from Calbiochem-Novabiochem International, 
San Diego, California, USA. Ro 31-8220 was a generous gift from Dr. G. Lawton (Roche 
Products Ltd, Herefordshire, United Kingdom). 
The concentrations given for the various reagents in each experiment described in 
this chapter are final concentrations in a total incubation volume of 1 ml. 
2.1 .3 I S O T O P E S A N D R A D I O I M M U N O A S S A Y K I T S 
These were obtained from the Radiochemical Centre, Amersham (Little Chalfont 
Buckinghamshire, United Kingdom) 
(1) Nai25iodide. (Code IMS30) This was supplied in dilute NaOH, pH 7-11. The 
concentration was approximately 100 mCi ^^ I^/ml, and the specific activity approximately 
17 mCi i25i/|jg of iodine at the reference date. 
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(2) [^Hl-cAMPassay kit. (Code TRK 500) The contents were 180 pmol of [8-^H] 
adenosine 3，，5'-cyclic phosphate (5|JCi), specific activity 0.028|JCi/pmol, adenosine 3，，5'-
cyclic phosphate standard, Tris/EDTA assay buffer (50mM Tris-HCL and 4mM EDTA, pH 
7.5), binding protein (purified from bovine muscle) and charcoal adsorbent. 
2.1.4 CULTURE MATERIALS AND CHEMICALS 
Minimum essential medium (MEM) (Eagle 1959), horse serum, amino acids, L-
glutamine and penicillin/streptomycin were obtained from Gibco BRL (Grand Island, New 
York, USA). Culture dishes and flasks were obtained from Falcon Dickinson Labware 
(Franklin Lakes, New Jersey, USA). Dibutyryl cAMP (dbcAMP), 3-isobutyl-l-
I 
methylxanthine (IBMX), N-2-hydroxyethylpiperazine-N'2-ethanesuphonic acid (HEPES), 
and bovine serum albumin (BSA) were purchased from Sigma Chemical Company (Saint 
Louis, Missouri, USA). All other chemicals and reagents were of analytical grade and were 
obtained from Sigma Chemical Company unless otherwise specified. 
2.1.5 PREPARATION OF MATERIALS 
2.1.5.1 PREPARATION OF PRIMARY CULTURES OF ASTROCYTES 
Primary cultures of mouse astrocytes were prepared according to the method 
described by Hertz et.al. (1978) with some modification. l-2days old neonatal mice were 
decapitated with scissors. The subependymal germinal plates from the lateral ventricles of 
the mouse brains were dissected free of meninges, chopped into pieces, and placed in 
culture medium containing minimum essential medium (MEM) with a double concentration 
of all amino acids except L-glutamine (2.8 mM), a quadruple concentration of MEM 
vitamin solution, 20 % horse serum, 200 iu/ml of penicillin and 200 of streptomycin. 
Brain tissue was vortex-mixed vigorously for two seconds to dissociate the brain cells. 
Following filtration through a 10|j.m membrane filter, the cell suspensions were distributed 
into 35-mm diameter culture dishes Cells were incubated at 37°C in a humidified incubator 
with a mixture of 5% CO2/95 % air, the pH being maintained at 7.3. The culture medium 
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was changed every two to three days. After 14 days the cultured cells were harvested as 
undifferentiated astrocytes. 
2.1.5.2 PREPARATION OF MEDIUM AND BINDING BUFFER 
Deionized distilled water was measured to a total volume equal to 5% less than 
the final required volume of the medium, using a mixing container that was as close to 
the final volume as possible. Powdered medium was then added to the water with gentle 
stirring. Add 22g ofNaHCOs was added to 10 liters of medium. This was then dilute to 
the desired volume with water and stirred until the chemicals dissolved. The pH of the 
medium was adjusted to 7.35 (using IN NaOH or IN HCL). The container was kept 
closed until the medium was filtered. MEM was sterilized immediately by membrane 
filtration and kept in sterilized bottles. For 10% serum supplemented MEM, 50ml of 
horse serum was added to 450ml of MEM; and for 20%, 100ml of horse was added to 
400ml of medium. To each bottle of medium, 10ml of MEM amino acids solution, 15ml 
of MEM vitamins, 10ml of penicillin/streptomycin and 2ml of L-glutamine was added. 
The pH of the medium (pH7.2-7.4) was again adjusted by adding an appropriate amount 
of 2N NaOH. Binding buffer for receptor binding and second messenger studies was 
prepared by adding 5gm BSA and 2.3 gm (lOmMM) HEPES to 1 litre of serum-free 
MEM, with a pH of 7.3 at 22�C. 
2.1.5.3 PREPARATION OF ^^^I-LABELLED VASOACTIVE PEPTIDES 
Monoiodinated rat AM or rat CGRP of high specific activity was prepared by the 
lodogen method. lodogen was obtained from Pierce, Rockford, Illinosis, USA. 2 mg of 
iodogen was dissolved in 2ml of chloroform, then diluted stepwise to give a final 
concentration of 10 nM/100|Jl. Then lOOfjl aliquots (10 nM iodogen/tube) were added to 
1.5 ml Eppendorf tubes (Hamburg, Germany). After evaporation of the chloroform at 37°C 
in an oven, the iodogen-coated tubes were stored at -20°C until use. 
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Radioiodination was initiated by adding 65|Jl of 0.2 Monophosphate buffer (37.53 
gm dipotassium hydrogen phosphate and 4.9 gm potassium dihydrogen phosphate in 1 litre 
of water, pH 7.4) and 15|Jl Na^ ^^ I to an iodogen coated tube. 20 |Jg of peptides (AM or 
CGRP) in 20|Jl of double distilled water was added one minute later. The iodination mixture 
was allowed to react at room temperature for 5 mins，then applied immediately to a CI8 |J 
Bondapak column (Water Associate TM 3.9X300 mm, Milford, Massachusetts, USA) and 
equilibrated with 18% acetonitrile. HPLC purification of mono- -peptides was then 
performed by eluting with a linear acetonitrile gradient of 18-26.4% in 58 mM phosphate 
buffer (6.9 gm sodium dihydrogen phosphate in 1 litre water, pH adjusted to 2.9 with IM 
orthophosphoric acid), on a slope of 0.28 %/min and at a flow rate of Iml/min. 0.5 ml 
fractions were collected into tubes containing 0.5 ml of 0.5% bovine serum albumin in 
distilled water and 10|Jl aliquots taken for counting in a y-coimter. Purification using HPLC 
yields pure monoiodinated AM and CGRP, totally distinct from other reaction products (as 
shown in figures 3 and 4). The specific activity of monoiodinated AM, calculated by self-
displacement with anti- AM antiserum (Chiang, 1987), was as high as 1400Ci/mmol, the 
same calculated method as of monoiodinated CGRP. The result tracer preparation was 
aliquoted and stored at -20°C. It could be used for up to 6-8 weeks without significant loss 
of immunoreactivity. The radioactivity of the ^^^I-radiolabelled vasoactive peptides bound 
to cultured mouse astrocytes in the receptor binding experiments was determined in a y-
coimter (Auto-gamma 5650, Packard Instrument Company, Connecticut, USA). The 
counting efficiency of the counter was approximately 74%. The background count was 
determined using empty RIA tubes and was less than 100 counts per min. 
2.1.6 MEASUREMENT OF CELLULAR CYCLIC AMP 
The cells in the dishes were frozen at -70°c for 2 hours, and the cells were then 
allowed to dissolve at room temperature. The TCA extractable material was then 
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Fig 3 Monoiodinated AM 
Reverse-phase HPLC purification of '^ I^-AM after radiolabelling by iodogen. The first 
radioactive peak corresponds to and the second major peak corresponds iodinated 
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ether. The supernatant ether was aspirated by water suction and the tubes were then 
placed into hot water to evaporate residual ether. The aqueous layer was preserved and 
freeze-dried overnight. Cell debris was dissolved with 0.5N NaOH for protein 
determination using the method ofLowry et al (1951). 
The freeze-dried TCA extracted samples were assayed for cAMP using the 
Amersham cAMP RIA kit which contains: assay buffer (50mM Tris-HCL and 4mM EDTA, 
pH7.5), cAMP standard (16pmol stock concentration), [^ HJ-cAMP (with a specific activity 
of 0.02mCipmol), binding protein, charcoal adsorbent. 
The methodology of the cAMP assay followed that outlined with the Amersham kit. 
Briefly, the assay is based on the competition between unlabelled cAMP and a fixed 
quantity for a protein which has a high specificity and affinity for cyclic AMP. The amount 
of labeled protein-cAMP complex formed is inversely related to the amount of unlabeled 
cAMP present in the assay sample. Measurement of the protein-bound radioactivity enables 
the amount of unlabelled cAMP in the sample to be calculated. 
The procedures of the cAMP assay were as follows. A standard curve was 
obtained by adding standard cAMP (known concentrations of reagent 2: range 0 � 1 6 pmol) 
into the tubes containing [^ H] cAMP (reagent 3) and binding protein. The reagent 
containing unknown cAMP was added into the tubes containing [^ H] cAMP and binding 
protein. Lastly the known and unknown cAMP (which had been labelled with [^ H]) were 
counted using a p-counter. The amounts of cAMP in the samples were read from the 
standard curve. 
Separation of the protein bound cAMP from the unbound nucleotide is achieved by 
adsorption of the free nucleotide on to coated charcoal, followed by centrifugation .An 
aliquot of the supemant was then removed for liquid scintillation counting. The 
concentration of unlabelled campaign the sample was then determined from a linear 
standard curve. 
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The following procedure was followed: Place into 9 assay tubes (Eppendorf), 
pipette 90|il of the buffer (reagent 1) was pipetted into the assay tubes 1. These tubes 
are for the determination of the blank counts per min for the assay; 30 of the buffer 
(reagent 1) was pipetted into the assay tubes 2 for determination of binding in the 
absence of unlabelled cAMP. Starting with the highest level of standard cAMP add 50|LI1 
of each dilution was added into assay tubes 3-9 for determination of the standard curve. 
30|il of each unknown sample was added into the additional assay tubes as appropriate. 
30^1 labelled cAMP [reagent 3] was added to each assay tube. 60|il of the binding 
protein [reagent 2] was added to assay tubes 2-9 and to each assay tube containing an 
unknown sample. All tubes were then vortex mixed for about 5 seconds. The ice bath 
o 
containing the tubes was then placed into a refrigerator at 2-8 C and left for two hours. 
At least 15 mins before the end of the incubation time, 20ml of ice cold distilled water 
was added to the charcoal reagent stand the container in an ice-bath and stirred 
continuously during use. 60|J1 of the charcoal suspension was added to all tubes, and 
vortex mixed briefly. The tubes were replaced into the ice bath. Charcoal was not added 
to more tubes than can be centrifliged in one bath. The tubes were centrifuged to 
sediment the charcoal. The tubes should be centrifuged for not less than Imin and no 
more than 6 min after addition of charcoal to the last tube, in a bath. Without disturbing 
the sediment 120 [J1 supernatant was removed from each tube after centrifuging, and 
placed in scintillation vials for counting. Total counts were determined using a 
BECKMAN. LS 3801 scintillation counter, each scintillation vial containing 3 ml 
Optiphase-HiSafe 2 and 120 [J1 CAMP supernatant. 
To determine the blank counts per min (cpm) for the assay, the cpm for tubes 1 were 
arranged. To determine the cpm bound in the absence of unlabelled cAMP (Co), the cpm for 
tubes 2 were arranged and subtracted from the blank cpm. To determine the cpm bound in 
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the presence of standard or unknown unlabelled cAMP (Cx), the cpm for each of tubes 3-9 
were arranged as were the cpm in the additional tubes which contain unknown samples. The 
blank cpm from each resultant was subtracted to give the cpm bound in the presence of 
standard or unknown (Cx). CQ/CX was calculated for each level of cAMP and unknown. 
Co/Cx was plotted against pmoles of inactive cAMP/tubes on linear graph paper. A straight 
line should be obtained with an intercept of 1.0 on the ordinate. From the CQ/CX value for 
the sample, the number ofpmols of inactive cAMP was read from the standard curve. 
Radioactivity of tritiated chemicals was determined in a liquid scintillation counter 
(Model LS 3801, Beckman Instruments Inc., Palo Alto，California, USA) with a counting 
efficiency of about 50%. The amount of radioactivity was expressed in terms of cpm in the 
presence of scintillation fluid. The background count measured with scintillation fluid alone 
was 40-80 cpm. 
The scintillation fluid was prepared by adding 20gm of 2,5-diphenyloxazole (PPO) 
and 2 gm of l,4-bis[2-{5- phenyloxazolyl}]benzene (POPOP) to 3.33 L of toluene and 1.67 
L of Triton X-100 to give a final volume of 5L. Radioactivity of tritiated chemicals in each 
sample was determined in 3 ml liquid scintillant. 
2.1.7 DETERMINATION OF PROTEIN CONTENT OF CULTURED 
ASTROCYTES 
The protein content of monolayer astrocytes in 35-mm-diameter culture dishes 
was used to express and compare the degree of ligand binding and the extent of 
accumulation of second messengers elicited by the vasoactive peptides. 
It was determined using the method of Lowry et al (1951). Lowry solution A was 
prepared with CuSCU (0. l%w/v), sodium potassium tartrate (1% w/v) and sodium carbonate 
(20gm/l) in NaOH (4gm/l) in a ratio of 1:1:100.Lowry solution B consisted of Folin and 
Ciocalteu's phenol reagent. Briefly, 1 ml of 0.5 M NaOH was added to cell residues in 
culture dishes and kept at room temperature for 2 hours. 250 |Jl of M HCL and 1 ml Lowry 
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solution A were added to 250 (JL of the cell lysate, and mixed at room temperature for 15 
mins. 0.1 ml of 50% Follin Phenol reagent in water was then added to the sample tube and 
mixed at room temperature for 20 mins. Optical density (OD) at 750-nm/490 nm was then 
read with a photometer using BSAas the protein standard. 
2.2 METHODS 
2.2.1 LIGAND BINDING: MEASUREMENT OF ^^ I^-AM AND ^^^I-CGRP 
BINDING 
2.2.1.1 BINDING KINETICS 
For association studies, duplicate samples of monolayer astrocytes in 3 5-mm culture 
dishes were washed twice with binding buffer containing 5g/l BSA and lOmM HEPES in 
serum-free MEM, pH7.3 and incubated for time intervals up to 120 min. at 22�C with 1 ml 
of binding buffer containing 0.2 nM ^^ I^-labelled AM or ^^ I^-labelled CGRP. At the end of 
the incubation, the cells were washed twice with 2-ml ice-cold binding phosphate buffered 
saline (PBS, pH7.4) to remove unbound tracer and were then digested with 0.5 N NaOH for 
2 hours at room temperature. Bound ^^ I^-AM and ^^ I^-CGRP were determined in a 丫-counter 
(Beckman). Units were expressed as (mean± SEM) fmol /mg protein. Results are means of 
duplicate determinations from three experiments. 
2.2.1.2 DETERMINATION OF SPECIFIC BINDING OF ^^ I^-AM AND 
CGRP 
Duplicate samples of washed astrocytes were incubated with 1 ml of binding buffer 
containing ^^ I^-AM and ^^ I^-CGRP at varying concentrations (0-1.5nM) for 120 min. at 
22°C for total binding. Non-specific binding was determined in the presence of an excess of 
cold peptide (lOOnM). Specific binding was defined as total binding minus non-specific 
binding. At the end of the incubation, the cells were washed twice with 2-ml ice-cold 
binding phosphate buffered saline (PBS, pH7.4) to remove unbound tracer and were then 
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digested with 0.5 N NaOH for 2 hours at room temperature. Bound ^^ I^-AM and ^^ I^-CGRP 
were determined in a y-counter (Beckman). Units were expressed as (mean± SEM) fmol 
/mg protein. Results are means of duplicate determinations from three experiments. 
2.2.1.3 COMPETITION BINDING STUDIES 
Duplicate samples of washed astrocytes were incubated for 120 min. at 22°C with 
increasing concentrations of ^^ I^-AM or ^^ I^-CGRP in 1 ml of binding buffer containing 
100|aM of corresponding unlabelled AM or CGRP. At the end of the incubation, the cells 
were washed twice with 2-ml ice-cold binding phosphate buffered saline (PBS, pH7.4) to 
remove unbound tracer and were then digested with 0.5 N NaOH for 2 hours at room 
temperature. Bound ^^ I^-AM and ^^ I^-CGRP were determined in a y-counter (Beckman). 
Units were expressed as (mean士 SEM) fmol /mg protein. Results are means of duplicate 
determinations from three experiments. 
2.2.2 BIOCHEMICAL INTERACTIONS BETWEEN ET3, AM, CGRP AND 
PKC-ANALOG 
2.2.2.1 DETERMINATION OF THE PRODUCTION OF CAMP IN RESPONSE 
TO AM AND CGRP 
To study the dose responses of AM and CGRP-stimulated cAMP accumulation, 
monolayer astrocytes in 35-mm-diameter culture dishes were washed twice with buffer 
containing 1 g/L BSA and lOmM HEPES in serum-free minimal essential medium (MEM) 
(pH 7.3). They were then incubated with concentrations of 0-1000 nM AM or CGRP in 
buffer supplemented with 1 mM of the phosphodiesterase inhibitor EBMX at 22°C for 10 
mins. Intracellular cAMP was released with 1 ml 6% (w/v) TCA, and measured as 
described in 2.1.6. Units were expressed as (mean± SEM) nM /mg protein. Results are 
means of duplicate determinations from three experiments. 
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2.2.2.2 DETERMINATION OF THE EFFECT OF PMA ON AM AND CGRP-
DEPENDENT CAMP PRODUCTION 
To study the time-related effects of PMA on AM and CGRP-dependent cAMP 
accumulation, monolayer astrocytes in 35-mm-diameter culture dishes were washed twice 
with buffer containing 1 g/L BSA and lOmM HEPES in serum-free minimal essential 
medium (MEM) (pH 7.3), then incubated with lOOnM PMA in buffer supplemented with 1 
mM of the phosphodiesterase inhibitor IBMX at 22�C at various intervals (0-240 min.). 
Following preincubation, 100 nM AM or CGRP was added to mouse astrocytes for 10 min. 
To determine the dose-related effects of PMA on AM and CGRP-induced cAMP 
production, mouse astrocytes were incubated with varying concentrations (lpM-l|LiM) of 
PMA in buffer supplemented with 1 mM IBMX at 22�C for 60 min, followed by incubation 
with lOnM of either AM or CGRP for 10 min. Intracellular cAMP was released with 1 ml 
6% (w/v) TCA, and measured as described in 2.1.6. Units were expressed as (mean 士 SEM) 
nM /mg protein. Results are means of duplicate determinations from three experiments. 
2.2.2.3 DETERMINATION OF THE EFFECT OF THE PHORBOL ESTERS ON 
AM AND CGRP-DEPENDENT CAMP PRODUCTION 
To determine the effects of the PKC agonist, PDBu and inactive phorbol ester 
aPDD, on AM and CGRP-induced cAMP production, mouse astrocytes were incubated 
with two concentrations (100 nM and IfiM) of PDBu or aPDD in buffer supplemented with 
1 mM IBMX at 22°C for 60 min, followed by incubation with 100 nM AM and CGRP for 
10 min. Intracellular cAMP was released with 1 ml 6% (w/v) TCA, and measured as 
described in 2.1.6. Units were expressed as (mean± SEM) nM /mg protein. Results are 
means of duplicate determinations from three experiments. 
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2.2.2.4 ELUCIDATION OF ANTAGONISTIC EFFECT OF STAUROSPORINE 
AND RO 31-8220 
To examine the possible antagonist roles of staurosporine or Ro 31-8220 (PKC 
inhibitors) on phorbol ester-mediated suppression of AM or CGRP-dependent cAMP 
accumulation, mouse astrocytes were incubated with two concentrations (100 nM, l^iM) of 
staurosporine or Ro 31-8220 in buffer supplemented with 1 mM IBMX at 22�C for 30 min. 
Cells were then further incubated with 100 nM PMA for 60 min or with 1.0 nM ET-3 for 10 
min, and with lOOnM AM or CGRP for 10 min. Intracellular cAMP was released with 1 ml 
6% (w/v) TCA, and measured as described in 2.1.6. Units were expressed as (mean± SEM) 
nM /mg protein. Results are means of duplicate determinations from three experiments. 
2.2.2.5 DETERMINATION OF THE EFFECTS OF ET-3 ON AM AND CGRP-
DEPENDENT CAMP ACCUMULATION 
To study the time-related effects of ET-3 on AM and CGRP-dependent cAMP 
accumulation, monolayer astrocytes in 35-mm-diameter culture dishes were washed twice 
with buffer containing 1 g/L BSA and lOmM HEPES in serum-free minimal essential 
medium (MEM) (pH 7.3)，then incubated with 100 nM ET-3 in buffer supplemented with 1 
mM of the phosphodiesterase inhibitor IBMX at 22°C for various time intervals (0-
120min.). Following preincubation, 100 nM AM or CGRP was added to mouse astrocytes 
for 10 min. 
To determine the dose-related effect of ET on AM and CGRP-induced cAMP 
production, mouse astrocytes were preincubated with varying concentrations (IpM-l^iM) of 
ET-3, together with 10 nM AM or CGRP, in buffer supplemented with 1 mM IBMX at 
22°C for 10 min. Intracellular cAMP was released with 1 ml 6% (w/v) TCA, and measured 
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as described in 2.1.6. Units were expressed as (mean士 SEM) nM /mg protein. Results are 
means of duplicate determinations from three experiments. 
2.2.2.6 DETERMINATION OF THE EFFECTS OF PKC INHIBITION ON ET-3 
SUPPRESSION OF AM- AND CGRP-EVDUCED CAMP RESPONSES 
To determine the effects of the PKC antagonists: staurosporine and Ro 31-8220, on 
ET-3 attenuated AM and CGRP-dependent cAMP accumulation, mouse astrocytes were 
incubated with two concentrations (100 nM, l[iM) of staurosporine or Ro 31-8220 in buffer 
supplemented with 1 mM IBMX at 22°C for 30 min. This was followed by incubation with 
100 nM ET-3 together with 100 nM AM and CGRP for 10 min. Intracellular cAMP was 
released with 1 ml 6% (w/v) TCA, and measured as described in 2.1.6. Units were 
expressed as (mean士 SEM) nM /mg protein. Results are means of duplicate determinations 
from three experiments. 
2.2.2.7 ELUCIDATION OF ANTAGONISTIC EFFECT OF CYCLOHEXEMIDE 
The effects of the protein synthesis inhibitor, cycloheximide, on PMA attenuated 
AM and CGRP-dependent cAMP accumulation were examined by incubating the cells with 
two concentrations (10|IM, 100|LIM) of cycloheximide in buffer supplemented with 1 
mM IBMX at 22°C for 30 min. Further incubation with 100 nM ET for 60 min was 
performed followed by incubation with 100 nM AM and CGRP for 10 min. Intracellular 
cAMP was released with 1 ml 6% (w/v) TCA, and measured as described in 2.1.6. Units 
were expressed as (meant SEM) nM/mg protein. Results are means of duplicate 
determinations from three experiments. 
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2.3 STATISTIC ANALYSIS 
Unless otherwise specified, results are mean 士 SEM values of duplicate 
determinations from three experiments (n二6). Comparison of data between two groups was 
done by using Student's unpaired t-test. For multiple group comparisons, one-way or two-
way analysis of variance (ANOVA) was performed as appropriate. Any significant 
difference was evaluated fiarther using either Duncan's multiple range test, Dimnett s test, or 
the Bonferroni test to determine the differences between individual groups. A p-value of 
<0.05 was considered as statistically significant. 
Binding of vasoactive peptides to astrocyte receptors was analyzed with Prism 
(Versions 1.0 and 2.0 for Windows), Graphpad Software, San Diego, California, USA. This 
program can perform analysis of binding data using both non-linear regression and 
Scatchard Plot transformation. The non-linear regression analysis is based on the same 
principles of extra sum of squares test and the runs test as utilized by LIGAND (Munson 
and Rodbard 1980). For the early experiments described with LIGAND, these were shown 
to concur well in terms of the binding parameters and curve fitting of multiple site models 
of LIGAND binding. The program has the additional advantages of being easier to operate 
and of creating publication quality graphs. Thus, it was used for analysis of binding data 





3.1 BINDING KINETICS OF ''^I-AM AND ''^I-CGRP 
Figures 5 and 6 show that the time courses for association of ^I-AM (Fig 5) and 
�I -CGRP (Fig 6) to astrocytes were similar, an equilibrium was reached at approximately 
90-120 min. An incubation period of 120 min was therefore employed for subsequent 
binding studies. 
3.2 SPECIFIC BINDING OF ^^ I^-AM AND ^^^I-CGRP 
Figures 7 and 8 show saturable binding of ^^ I^-AM and ^^ I^-CGRP respectively. 
Binding data were analyzed by nonlinear regression using Prism (Graphpad Software, San 
Diego, California,USA). The programs showed that binding was mathematically consistent 
with a one-site model for both AM and CGRP. The saturated binding data saturated with 
AM is shown in Table 3 and with CGRP is shown in Table 4. Each experiment was 
performed in duplicate and each set of experiments was repeated three times (n=6). In each 
saturated binding experiment, different concentrations of iodinated-peptide was added to the 
astrocytes, therefore results from the three experiments are presented separately. 
In the results, the mean of B^ ax was 12.29±0.28 and 14.28±0.33 finol /mg protein 
for AM and CGRP respectively, and the means of the dissociation constants (Ka) were 
0.72±0.06 nM for AM and 0.1037±0.01 nM for CGRP respectively. Scatchard 
transformation of the specific binding data also revealed a single class of binding sites for 
both peptides. 
3.3 COMPETITION BINDING 
Figures 9 and 10 show the displacement of ^^ I^-AM and ^I-CGRP by their 
corresponding unlabelled AM or CGRP. Specific binding of ^^ I^-AM and ^I-CGRP was 
inhibited in a dose-dependent manner by the unlabelled AM and CGRP, respectively. The 
concentrations of unlabelled peptides (AM or CGRP) required for 50% displacement of 
specific binding of ^^ I^-AM and ^^ I^-CGRP were 0.658 nM for AM (Fig 9) and 0.112 nM 
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Fig 5 Time course of AM receptor-binding 
Time course of � I - A M binding to astrocytes when incubated at 4�C for different time. Each 
point is the mean of duplicates in a typical experiment. The Y axis shows binding expressing 
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Fig 6 Time course of CGRP receptor-binding 
Time course of � i - C G R P binding to astrocytes when incubated at 4°C for different time. 
Each point is the mean of duplicates in a typical experiment. The Y axis shows binding 
expressing as a ratio of maximum binding. 
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Scatchard plot of specific binding 丨25I-AM to AM receptor on astrocyte cells 
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Specific binding was obtained by subtracting nonspecific binding from 
total binding in the presence of 100nM unlabeled CGRP,data points 
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Scatchard plot of specific binding 125I_CGRP to CGRP receptor on astrocyte cells 
Fig 8 CGRP saturation binding curve 
Total binding Nonspecific binding Specific binding Results 
(fmol/mg protein) (fmol/mg protein) (fmol/mg protein) 
1-826 0.431 1 .395 ^ 7 m f m n l / m g pmft^in 
1 5 2 1.906 1.614 
6 . 5 3 3 • 3 .84 2 . 6 9 3 y .A y c 
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Total binding Nonspecific binding Specific binding Results 
(fmol/mg protein) (fmol/mg protein) (fmol/mg protein) 
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3.11 U Z 124 
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198 L28 
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Table 3 Saturated binding of AM in astrocytes 
Total binding Nonspecific binding Specific binding Results 
(fmol/mg protein) (fmol/mg protein) (fmol/mg protein) 
L M 0.83 : Bmax: 14.04 faiol/mg prote in 122 ^ 
17.94 ^ 11.43 rr i n , � M 
11.^ 1 4 . 9 2 1 0 . 
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(fmol/mg protein) (fmol/mg protein) (fmol/mg protein) 
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Table 4 Saturated binding of CGRP in astrocytes 
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Fig 9 AM competition binding curve 
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AM, binding data represent pooled data from 3 experiments. 
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Fig 10 CGRP competition binding curve 
� I - CGRP together with different concentration of unlabelled 
CGRP, binding data represent pooled data from 3 experiments. 
Each performed in duplicate. 
3.4 DOSE RESPONSE OF ADRENOMEDULLIN AND CGRP-STIMULATED 
CAMP PRODUCTION 
Figures 11 and 12 show the dose responses of AM- and CGRP-stimulated cAMP 
accumulation following incubation of astrocytes with concentrations of O-lOOOnM AM or 
CGRP for 10 min respectively. It was shown that 100 nM AM and 100 nM CGRP 
stimulated a marked increase in cAMP production from a basal value of 130.4±5.4 to 
250.2+15.2 pmol /mg protein for AM (EC50二72 nM) (Fig 11), and from 112.3士 15.1 to 
608.0±27.5 pmol /mg protein for CGRP (EC50二66 nM) (Fig 12). 
3.5 EFFECTS OF PHORBOL ESTERS ON AM AND CGRP-DEPENDENT 
CAMP ACCUMULATION 
Preliminary experiments showed that preincubation of astrocytes with 100 nM PMA 
from 0-240 min progressively suppressed AM and CGRP-induced increments of cAMP. As 
there was already substantial suppression of cAMP accumulation at 60 min, subsequent 
dose-response experiments with phorbol esters (PMA, PDBu, and aPDD) were therefore 
conducted using a 60-min preincubation time. Results are mean 士 SEM values of duplicate 
determinations from three experiments (n=6). 
Pretreatment with PMA for 60 min had no effect on basal cAMP production, 
whereas PMA suppressed AM and CGRP stimulated cAMP production in a dose-dependent 
manner, from 491.3±19.8 to 286.4±35.5 pmol/mg protein for AM, and from 2241.5±41.3 to 
1298.8+34.1 pmol/mg protein for CGRP, (p<0.05) (Figl3a and 13b). Likewise, PDBu at a 
concentration of lOnM, significantly suppressed the cAMP increment from 491.3±19.8 to 
295.1±31.5 pmol/mg protein for AM and from 2241.5±41.3 to 1269.9±20.2 pmol/mg 
protein for CGRP, whereas aPDD, which does not stimulate PKC, had no significant 
suppressive effect up to a concentration of lOOOnM (Fig 13a and 13b). 
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Fig 12 Dose response of CGRP-stimulated cAlvfP accumulation in mouse astrocytes. 
Astrocytes were incubated with CGRP (0-1 OOO>nM for min. Results are mean ± SEM 
values of triplicate detenninations from three experilnents. 
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Fig 13a PMA, PDBu, aPDD effects on AM 
Astrocytes were preincubated with PMA InM, 10 nM, 100 nM, with PDBu lOnM, lOOnM, 
with aPDD InM; lOnM; lOOnM, for 60 mins respectively, then incubated with lOOnM AM for 
10 min. lOOnM PMA only, lOOnM PDBu only, lOOnM aPDD only, lOOnM AM only, medium 
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Fig 13b PMA, PDBu, aPDD effects on CGRP 
Astrocytes were preincubated with PMA InM, 10 nM, 100 nM, with PDBu lOnM, lOOnM, 
with aPDD InM; lOnM; lOOnM, for 60 mins respectively, then incubated with lOOnM CGRP 
for 10 min. 1 OOnM PMA only. 1 OOnM PDBu only, 1 OOnM ctPDD only, 1 OOnM CGRP only and 
medium only were done as controls. Results are mean 土 SEM values of duplicate determinations 
from three experiments. 
3.6 EFFECT OF PMA ON AM AND CGRP-DEPENDENT CAMP 
ACCUMULATION 
Figure 14 showed the time course of PMA-induced inhibition of AM- and CGRP-
stimulated cAMP accumulation. Preincubation of astrocytes with or without PMA for 0-4 
hours induced effect in the AM or CGRP dependent cAMP response. Maximal inhibition 
time point occur at 60 min. Subsequent dose-response experiments with PMA were 
therefore performed using a 60 min preincubation time. 
Figure 15 shows the dose-responses of PMA- induced inhibition of AM- and 
CGRP-stimulated cAMP accumulation. Incubation of astrocytes with PMA did not affect 
the basal level of cAMP, whereas suppression was observed for both AM and CGRP-
stimulated cAMP production in a dose-dependent manner, lOOnM AM and CGRP 
stimulated cAMP production from a basal value of 106.2±9.8 pmol /mg protein to 
369.9±11.3 pmol /mg protein and 1496.3+32.1 protein respectively in the absence of PMA. 
This response was decreased to 179.8±17.4 and 660.79±24.8 respectively in the presence of 
lOOnM PMA (maximal inhibition concentration). With a half-maximal inhibitor 
concentration (IC50) of 1.013 nM for AM and 1.857 nM for CGRP (Fig 15), maximal 
inhibition, at a dose of lOOnM PMA, resulted in a 49% reduction of the astrocyte cAMP 
response to AM and 58% reduction of the response to CGRP respectively. 
3.7 EFFECT OF ET-3 ON AM AND CGRP-DEPENDENT CAMP 
ACCUMULATION 
Figure 16 showed preincubation of astrocytes with ET-3 from 0-120 min. 
Simultaneous addition of ET-3 and AM and CGRP induced a rapid and significant (-50%) 
inhibition in the AM and CGRP-dependent cAMP responses. Subsequent dose-response 
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Fig 14 Time course for PMA-induced inhibition of (a) AM- or (b) CGRP-stimulated cAlvlP 
pr,oduction. Astrocytes were preincubated with 100 nM PMA in buffer supplemented with 1 
mM IBMX at 22°C for 0-240 mins, then expose to 100 nM AM or CGRP for 10 mins. 
Results are expressed as mean ± SEM of duplicate determinations from three separate 
experiLnents (n=6). (a-without PMA and e-with PMA) 
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Fig 15 Dose response ofPMA-induced inhibition of (a) AM- or (b) CGRP-stimulated cAMP 
production. Astrocytes were preincubated with PMA (O.Ol-lOOOnM) in buffer supplemented 
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mins. Results are expressed as mean 士 SEM of duplicate determinations from three separate 
experiments (n=6). 
350-1 
(a)- on AM 
300- T 







乏 150- T I 
100- • I 
5Q 
0 15 30 60 - -
Time (min) 








500-1 , , � . I ^ 
0 15 30 60 
Time (min) 
Fig 16 Time course for ET-3-induced inhibition of (a) AM- or (b) CGRP-stimuIated cAMP 
production. Astrocytes were incubated with 1.0 nM ET-3 and 100 nM AM or 100 nM CGRP 
for 10 mins in buffer supplemented with 1 mM IBMX at 22°C Results are expressed as 
mean 土 SEM of duplicate determinations from three separate experiments (n=6). 
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Incubation of astrocytes with ET-3 did not affect the basal level of cAMP. However, 
as shown in Figure 17，ET-3 suppressed AM- and CGRP- stimulated cAMP production in a 
dose-dependent fashion. lOOnM AM and 100 nM CGRP both stimulated cAMP production 
from a basal value of 106.2±9.8 pmol/mg protein to 369.9±11.3 pmol/mg protein for AM 
and 1496.3土32.1 protein for CGRP in the absence of ET-3. This response was reduced to 
179.8±17.4 and 660.79±24.8 respectively in the presence of 100 nM ET-3 (maximal 
inhibition concentration). With a half -maximal inhibitor concentration (IC50) of 0.068 nM 
for AM and 0.082nM for CGRP, maximal inhibition at lOOnM ET-3, resulted in a 49% 
reduction of the astrocyte cAMP response to AM and 44% reduction of the response to 
CGRP respectively. 
3.8 THE EFFECTS OF STAUROSPORINE, RO 31-8220 
Figure 18 and 19 show the effects of staurosporine (lOOnM) and Ro 31-8220 (1.0 
nM) on ET-3 (100 nM) or PMA (100 nM). 
1.0 nM ET-3 alone reduced AM and CGRP-dependent cAMP production from 
680.0±37.0 to 412.1±：31.5 pmol /mg protein for AM (Fig 18) and from 1237.7+55.8 to 
701.84±3.8 pmol /mg protein for CGRP (Fig 19) (p<0.05). In the absence of ET-3, 
staurosporine (lOOnM) or Ro 31-8220(100nM) did not affect AM and CGRP-dependent 
cAMP production significantly. However, they blocked ET3-mediated suppression of the 
AM and CGRP-dependent cAMP response: Staurosporine and Ro 31-8220 reverse it to 
564±19.9, 524.5±14.8 pmol /mg protein respectively for AM (Fig 18); and to 1256.58±19.9， 
1108.34+42.5 pmol /mg protein respectively for CGRP (Fig 19) (P<0.05). 
lOOnM PMA alone reduced AM and CGRP-dependent cAMP production from 
680.0土37.0 to 351.0土26.8 pmol/mg protein for AM (Fig 18) and from 1237.7±55.8 to 
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Fig 17 Dose response of ET-3-induced inhibition of (a) AM- or (b) CGRP-stimulated cAMP 
production. Astrocytes were incubated with ET-3 (O-lOOOnM) and AM or CGRP lOOnM for 
10 mins in buffer supplemented with 1 mM IBMX at 22^C. Results are expressed as mean 土 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































staurosporine (lOOnM) or Ro 31-8220(100nM) did not affect AM and CGRP-dependent 
cAMP production significantly. However, they blocked PMA-mediated suppression of the 
AM and CGRP-dependent cAMP response: Staurosporine and Ro 31-8220 reverse this to 
564+19.9, 524.5+14.8 pmol /mg protein respectively for AM (Fig 18); and to 1020.5±46.8, 
987.9+26.5 pmol /mg protein respectively for CGRP (Fig 19) (P<0.05). 
3.9 EFFECT OF CYCLOHEXEMIDE ON THE SUPPRESSIVE ACTION OF ET3 
10|LIM cycloheximide exhibited a significant reversal of the suppressive action of 
ET-3 on the AM- stimulated cAMP level from 583.5+52.0 to 813.4±89.0 pmol/mg 
protein; and from 1208.3±27.1 to 1503.7±23.7 pmol/mg protein with CGRP (P<0.05). 
This inhibitory action was already observed at lOjuM of cycloheximide, and was not 
significantly different with lOOjuM of cycloheximide. This inhibitory action was already 
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Fig 20 Effect ofcyoloheximide on the suppression action of ET-3 on AM, 
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Fig 21 Effect of cycloheximide on the suppression action of ET-3 on CGRP. . 
Astrocytes were preincubated with cycloheximide (10-100 ^M) for 30 mins. then exposed to 
100 nM CGRP for 10 min. Results are expressed as mean 土 SEM of duplicate determinations 







The results indicate the presence of specific-binding sites for AM and CGRP 
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on cell membranes of cultured mouse astrocytes. Binding studies using [ I] AM and 
[i25I]CGRP have revealed the presence of a single class of high-capacity and affinity 
receptors, in the case of both peptides. Although the mean Bmax of AM (with 12.4 士 
0.3 fmol/mg protein) was not significantly different than that of CGRP (Bmax 14.3±0.3 
fmol/mg protein), the Ka of AM was significantly higher from that of CGRP, being 
0.717±0.063 nM for AM and 0.10士0.01 nM for CGRP respectively. Using competition 
binding, the value of IC50 were 0.658 nM for AM and 0.112 nM for CGRP. If AM and 
CGRP share the same binding sites, this can be taken to indicate that the receptor 
binding capacities of AM and CGRP are similar. However, the affinity of the receptors 
for AM is weaker than for CGRP when the approach using saturated-binding 
experiments is approved (Kd of AM > Kd of CGRP). This is consistent with the results 
of the competitive-binding experiments (IC50 of AM > IC50 of CGRP). The 
demonstration that CGRP elicited a 3 fold greater cAMP response than AM in 
undifferentiated astrocytes also suggests that CGRP have a greater potency in 
stimulating astrocytes to produce cAMP. However, if AM and CGRP do not share the 
same binding sites on astrocytes, one cannot directly compare their receptor binding 
kinetic events. It has been shown that the receptors of AM, CGRP and amylin are co-
expressed in pancreatic beta-cells of rats, and physiological data also shows that AM 
functions in the cardiovascular system are mainly mediated through a CGRP receptor in 
pancreatic beta-cells of rats (Martinez et al., 2000). This indicates that AM share the 
same binding sites with CGRP in rat pancreatic beta-cells. It has also been shown that 
CGRP and AM both attenuated the contractile response to galanin, and the responses to 
both CGRP and AM were abolished by CGRP in isolated non-pregnant rat uteri. The 
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results demonstrate the presence of AM and specific binding sites for both AM and 
CGRP in the rat uterus (Upton et al., 1997). But the ineffectiveness of CGRP to displace 
radiolabelled AM from its binding sites, to inhibit AM-induced glomerular cAMP 
formation, and to prevent AM-induced renal vasodilation supports the hypothesis that 
AM alters renal hemodynamics by interacting with AM- and not CGRP-specific 
membrane receptors (Hjelmqvist et al., 1997). This might indicate that AM does not 
share the same binding sites with CGRP in rat renal cells, at least, not completely. 
AM and CGRP bind not only to specific-binding sites but also to non-specific 
sites. The amount of AM and CGRP binding to the specific sites in astrocytes, occupies 
a smaller proportion of total binding, when compared to non-specific-binding. For 
example, the data in tables 3 and 4 show that when saturated-binding reaches the 
saturated state, the ratio of non-specific-binding/total-binding are about 60�70%, 
whereas the ratio of specific-binding/total-binding are about 30�40%. This indicated 
AM bind not only to the specific sites for AM but also to other sites on the cell surface. 
It has been shown that specific binding sites for AM are present in many regions of 
the human brain (cerebral cortex, cerebellum, thalamus, hypothalamus, pons and medulla 
oblongata). (Sone et al., 1997), as shown in (Table 5). It these studies the hypothalamus has 
the lowest number of AM binding sites (Bmax 30.0±2.8 fmol/mg protein). Comparison with 
human brain, cultured mouse astrocytes from the present study were extracted from the 
subependymal germinal plates from the lateral ventricles of mouse brains, it has the 
saturated binding capacity of Bmax 12.4 士 0.3 pmol/mg protein. This indicates that 
astrocytes in this region have the lowest number of AM binding sites as in other regions of 
human brain. 
Furthermore, a study of binding sites in the rat spinal cord showed that analysis of 
equilibrium competition by imlabelled CGRP gives a Bmax of 17.7 土 2.4 fmol/mg protein 
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.Region Specific binding (fmol/mg protein) 
Cerebral cortex 一 75.4±3.5""““ “ “ 
Cerebellum 66.5+4.5 ‘ 
Thalamus “ 117.2±6.4 -
Hypothalamus 30.0±2.8 — ‘ 
Poos 77.6 土 9.2 ‘ 
Medullar oblongata 88.8土6.3“ “ 
Values are mean 土 SEH 
Table 5 Regional distribution of '^ I^-AM binding sites in human brain 
(Sone et al., 1997 with modification) 
and a Kd of 0.18 ±0.01 nM (n=3), and by unlabelled AM give a Bmax of 723 士 71 fmol/mg 
protein and aKd of 0.18 士 0.01 nM (n=3) (Ali et al., 1996). Thus，the presence of abundant 
binding sites and AM mRNA and immunoreactivity anticipate an as yet undefined 
fiinction for this peptide (AM) in spinal cord. In our present study, the mean Bmax was 
12.4 土 0.3 and 14.3±0.3 finol/mg protein for AM and CGRP respectively, the Kd of AM 
was significantly higher than that of CGRP, being 0.717±0.063 nM for AM and 0.1010.01 
nM for CGRP respectively. This can also be taken to indicate a rapid release of AM and 
CGRP from rat or mouse brain to peripheral spinal cord, rather than storage. 
Eguchi et al. (1994a), using rat AM report the presence of a single class of 
high-affinity (Kd 13 nM) binding sites for rat AM in vascular smooth muscle cells. The 
apparent Kd of rat CGRP was 300 nM. The present study showed that the Ka is 0.7 nM for 
AM and Ka for CGRP is 0.1 nM in cultured mouse astrocytes. This indicates that the 
affinities of the binding sites for AM and CGRP in astrocytes are greater than those for AM 
and CGRP in vascular smooth muscle cells respectively, and suggests that the receptor 
binding of AM and CGRP may be tissue-specific. Specific receptors for AM and CGRP 
show different binding characteristics in different tissues of the same animal, as well as in 
different regions of the same organ. 
Coppock et al., (1999) showed that a rat fibroblasts cell line expresses a 
specific AM receptor (coupled to cAMP production) and also secretes AM, AM 
stimulated a rapid rise in intracellular cAMP levels in a dose-dependent manner with a 
maximal response seen at 100 nM. (Abe, 1998). This is consistent with the results seen 
in the studies reported in this thesis, in which the cultured astrocytes showed a marked 
increase in cAMP production induced by 100 nM AM (Fig 11). 
CGRP also stimulated the accumulation of cAMP by up to 30-fold in cultured 
neonatal astrocytes, half maximal stimulation being obtained at CGRP concentrations in 
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the range of 100-300 nM. These data provide evidence for the presence of functional 
CGRP receptors in astrocytes and suggest a role for CGRP as an intercellular messenger 
controlling the state of differentiation and activation of astroglial cells (Lazar et al., 
1991). Whereas CGRP was found to stimulate the accumulation of cAMP by 10- to 20-
fold, the effect of CGRP on cyclic AMP accumulation was completely reversed by the 
CGRP receptor antagonist, CGRP (8-37) (Priller et al., 1998). In the present study, the 
extent of the cAMP incremental response to CGRP (10�20-fold) and the concentrations 
of CGRP (100 nM) required for maximal stimulation are consistent with the data in 
these previously published reports. 
Natriuretic peptides (ANP, BNP and CNP) are potent stimulators of cyclic GMP 
production (Yeung et al., 1992). They exert their physiological effects in the cardiovascular 
system through an increase in cyclic GMP production, a second messenger of cellular 
system. Binding of ANP and BNP to cultured mouse astrocytes from different brain regions 
have also been shown to increase cyclic GMP production (Yeung et al., 1993). It has been 
shown that AM exerts various biological actions such as vasodilation, bronchodilation and 
natriuresis, by stimulating cAMP production through its specific receptors (Murabe et al., 
1998). The present study showed that AM and CGRP increase another second messenger, 
cAMP production, in astrocytes. Thus, cAMP has emerged as the major known mediator of 
the actions of AM and CGRP. 
ET-3 has been shown in the experiments reported in this thesis to exert a negative 
modulatory action on both AM- and CGRP-induced cAMP responses. The degree of 
maximal inhibition (49%) is similar to that exhibited by ET-3 in mediating dose-dependent 
suppression of cGMP production in response to C-type natriuretic peptide in which an 
inhibitory 66% reduction of the cGMP increment was demonstrated (Yeung et al., 1996b). 
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However, in the present study, the suppressive action of ET-3 had a rapid onset 
and the full inhibitory effect was achieved within a much shorter time frame when 
compared to PMA. Simultaneous addition of ET-3 and AM or CGRP induced a rapid 
and significant (50%) reduction in either the AM or the CGRP-dependent responses， 
whereas preincubation with PMA showed a slow inhibitory effect. Further, full 
suppression of AM- or CGRP-induced cAMP accumulation with ET-3 was achieved 
within 30 min of preincubation (Fig 16), in contrast to 60 min of maximal suppression 
of preincubation with PMA to achieve (Fig 14). 
Phorbol didecanoate and dioctanoylglycerol (activators of PKC) also effectively 
inhibited CGRP-dependent cAMP stimulation. Whereas 4 alpha phorbol didecanoate， 
an ineffective activator of PKC, had no inhibitory effect. It also has been shown that 
AM and CGRP induced cAMP production in astrocytes can be suppressed by the 
phorbol esters PMA and PDBu, both of which are activators of the PKC system 
(Castagna et al., 1982). This is analogous to two other sets of reported information: 
l.The inhibitory action of PMA on ANP-dependent cGMP production in rat 
adrenocortical carcinoma cells (Jaiswal et al, 1988); 2. The inhibitory action of PMA on 
CNP-dependent cGMP production in cultured mouse astrocytes cells (Yeung et al., 
1992). The role of PKC activation in mediating these inhibitory effects is supported by 
two other observations. First, aPDD, an inactive phorbol ester analogue that does not 
stimulate PKC (Castagna et al., 1982), did not suppress the AM and CGRP-induced 
cAMP response. Secondly, staurosporine, a potent PKC inhibitor (Tamaoki et al.， 
1986), blocked the inhibitory action of PMA. Staurosporine blocked the inhibition of 
cAMP formation by phorbol esters (Crook and Yabu, 1992). Astrocyte cAMP 
production, in response to lOOnM AM and CGRP, was however attenuated, but not 
fully blocked, even with high doses of PMA and PDBu (Fig 13a and 13b). This suggests 
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the likely presence of other additional regulatory mechanisms, in addition to the PKC 
system. 
The suppressive action of ET-3 was also reversed by Staurosporine, and Ro 31-
8220 (Fig 18 and 19). This raises the possibility that ET-3 may also activate PKC 
system, and thus altering the phosporylation state. This may explain why the PKC 
inhibitors can reverse the inhibitory effect of ET-3. 
10|LIM cycloheximide also partially reversed the suppressive effect of ET-3 on 
AM- and CGRP-induced cAMP production. This is similar to the previous report that 
100|LIM cycloheximide partially reversed the suppressive effect of E T - 3 on CNP-
induced cGMP accumulation (Yeung et al., 1996b). Cycloheximide has been shown to 
be capable of rapidly modifying the phosphorylating activities of protein kinases such as 
hepatic nucleolar protein and S6 kinase (Suzuki et al.，1987). Thus, ET-3 may act by 
modulating the activities of certain protein kinases through, as yet, undefined 
mechanisms. 
Taken together, these data suggest that the mechanism of ET-3 in suppressing AM-
and CGRP-dependent cAMP production is mediated, at least partially, through the activation 






(1) The results presented in this thesis characterizes the binding sites of AM and CGRP 
in cultured mouse astrocytes and demonstrates the presence of specific-binding sites for 
AM and CGRP in cultured astrocytes. 
(2) AM and CGRP may share, though not identical, but at least partial common 
receptors, and to exhibit different binding capacity and affinity: AM appear to have a 
lower capacity and affinity for binding to mouse astrocytes when compared to CGRP. 
(3) AM and CGRP bind not only to specific-binding sites but also to non-specific sites 
The amount of AM and CGRP binding to the specific binding sites in cultured mouse 
astrocytes, occupy a smaller proportion of total binding, compared to non-specific-
binding. 
(4) This study also investigated certain biochemical mechanisms underlying the central 
interactions between AM, CGRP and ET in cultured mouse astrocytes. 
(5) Activation of the PKC system was associated with suppression of AM and CGRP-
dependent cAMP accumulation in astrocytes. 
(6) ET-3 also exerted a rapid and potent inhibitory effect on astrocyte AM- and CGRP-
dependent cAMP accumulation. 
(7) The inhibitory effect of ET-3 on cAMP accumulation in response to AM and CGRP was 
partially reversed by inhibitors of PKC, suggesting that the PKC pathway partially accounts 
for the suppressive action of ET-3. 
(8) Cycloheximide also significantly attenuated the inhibitory effect of ET-3 on AM 
and CGRP-dependent cAMP accumulation within 30min of incubation. This raises 
the possibility that ET-3 may also act by modulating the activities of certain protein 
kinases and thus altering the phosporylation state of their substrate proteins. 
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AM- or CGRP-stimulated astrocyte cAMP response was attenuated by PKC 
activation and by ET-3. Although PKC is, in general, an important mediator of the 
actions of ET (Simonson and Dunn, 1990; Masaki and Yanagisawa, 1992), the 
present study suggest that ET-3 suppresses cAMP responses through the enhanced 
activity of certain kinases, with the PKC pathway playing, a relatively important 
but not exclusive role. The current studies reveal a potential mechanism whereby 
neuropeptides such as ET-3, AM and CGRP can interact within the CNS, in the 
central regulation of cardiovascular haemodynamics. This study helps to elucidate 
the receptor and effector systems of vasoactive peptides (AM, CGRP) in cultured 
undifferentiated astrocytes, and has examined possible biochemical pathways of 
interactions with ET-3 in the CNS. Coupled with evidence that astrocytes are 
capable of direct stimulation and modulation of signal transmission to neurons 
(Nedergaard et al, 1994), this study further enhances the understanding of cellular 
mechanisms underlying the central and peripheral actions of vasoactive peptides in 
haemodynamics and body fluid homeostasis, and also explore aspects of 
neuroendocrine regulation and the possible roles played by astrocytes. 
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Modula t ion of Adrenomedul l in- and Calcitonin Genc-rclated Peptide-stimulated Cyclic AiVtP 
Responses by Endothel in in Cul tured [VIouse Astocytes 
V.T.F. Yeung, S X S . Ho, C.F. Yeung, M.G. Nicholls', and C.S. Cockram 
Department of Medicine and Therapeutics, Chinese University of Hong Koog, Shatin, N.T. Hong Kong, 
China ancl*Department of Medicine, Christchurch Hospital, CHristchurcn, New Zealand, 
t 
Adreaomedullia (AN() and calcitonin gene-related peptide (CGRP) are structurally related potent 
vasodilatory peptides which are also expressed in the central nervous wstcm (CNS). ' Endothelins (ET) 
are a family of peptide hormones with potent vasoconstrictor activity. They have been shown to exist 
also as neuropeptides. We have previously demonstrated the existence ot specific AM receptors on 
mouse astrocytes which are coupled to cyclic AMP production. The apparently opposite biol(^icai 
actions of ET and AM/CGRP have prompted us to examine possible effects of ET-3 OQ AM- and CGRP-
iaduced cAMP responses in culturea mouse astrocytes, Corulueat astrocytes were incubated with AM or 
CGRP with and without ET-3 in I ml of minimal essential medium supplemented with. 1 mM of the 
jhosphodiesterase inhibitor IB M X for 10 min, which was previously shown to be the incubation period 
b r AM to produce maximal cAMP responses/ Basal astrocyte cAMP production was 14.4 土 1.1 
pmol/'mg protein (mean 土 SEM n « 6). cAMP increased to 84.2 土 14.9 pmol/mg protein in response to 
100 nM AM, whereas 100 nM CGRP stimulated cAMP production to 232 土 24.6 pmol/rag .protein. ET-3 
suppressed the cAMP responses to AM and CGRP m a dose-dependent manner^ with half maximal 
inhibitory concentrations (ICso) of 3 pM and 30 pM, respectively. Maximal inhibition was achieved at 100 
oM ET-3, which significantly attenuated AM- and CGRP-stimulatcd cAMP fonnatioQ to 34.7 ± 7.6 
pmol/mg protein and to 132.1 土 14.6 pmol/mg protein, respectively (p<0.05). Our results suggest that 
AM- and CGRP-elicited cAMP stimulation is negatively regulated by ET-3. These findings also raise the 
possibility that ET interact with AM and/or CGRP in the control of astrocyte function and neuroendocrine 
regulation. . . . ‘ • . 
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